Statistical Analysis Plan
Drug Substance MEDI4736 and tremelimumab
Study Code D4193C00002
Edition Number [ADDRESS_971962] of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_971963] of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 
(SCCHN)
Global Product Statistician
Date
Statistical Analysis Plan 
Study Code D4193C00002
Edition Number 04Date [ADDRESS_971964] OF ABBREVIATIONS .............................................................................. 8
AMENDMENT HI STORY................................................................................ 11
1. STUDY DETAILS ............................................................................................. 14
2. STUDY OBJE CTIVES ...................................................................................... 15
2.1 Co-Primary Objectives....................................................................................... 15
2.1.1 Secondary Objectiv es......................................................................................... 15
2.1.2 Safety Objectives ............................................................................................... 16
2.2 Study Design...................................................................................................... 17
2.3 Number of Patients ............................................................................................ 23
3. ANALYSIS SETS ............................................................................................. 25
3.1 Definition of Analysis Sets................................................................................. 25
3.1.1 Full Analysi s Set (FAS) ..................................................................................... [ADDRESS_971965] 1.1................................................ 30
[IP_ADDRESS] Site Investigator Assessment Using RECIST 1.1: Target Lesions (TLs) ............. 30
[IP_ADDRESS] Non-Target Lesions (N TLs) and New lesions..................................................... 34
[IP_ADDRESS] Site Investigator Assessment Using RE CIST 1.1: Overall Vi sit Res ponse .......... 36
4.2 Outcome Variables............................................................................................. 36
4.2.1 Prima ry Endpoint: Overall Survival (OS) ........................................................... 37
4.2.2 Secondary Endpoints .......................................................................................... 37
[IP_ADDRESS] Progression-Free Survival (PFS) ........................................................................ 37
[IP_ADDRESS] Ob jective Response Rate (ORR) ........................................................................ 38
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
[IP_ADDRESS] Duration of Re sponse (D oR).............................................................................. 38
[IP_ADDRESS] Disease Control  Rate (D CR).............................................................................. 39
[IP_ADDRESS] Proportion of Patients Alive and Progression Free at 6 Months (APF6) .............. 39
[IP_ADDRESS] Proportion of Patients Alive and Progression Free at 12 Months (APF12) .......... 39
[IP_ADDRESS] Proportion of Patients A live at 12 Mont hs (O S12) .............................................. 39
[IP_ADDRESS] Proportion of Patients A live at 18 Months (OS18).............................................. 39
[IP_ADDRESS] Proportion of Patients A live at 24 Mont hs (O S24) .............................................. 39
[IP_ADDRESS] Best Objective Response (BoR) ......................................................................... 40
[IP_ADDRESS] Time to Response ............................................................................................... 40
[IP_ADDRESS] Time fro m Rando mization to First Subsequent Therapy or D eath (T FST) .......... 40
[IP_ADDRESS] Time fro m Rando mization to Sec ond Subsequent Therapy or Death 
(TSST)............................................................................................................... 41
[IP_ADDRESS] Time fro m Rando mization to Sec ond Progression-Free Survival (PFS2) ............ 41
[IP_ADDRESS] Change in Tu mor Size........................................................................................ 41
4.3 Safety................................................................................................................. 42
4.3.1 Adverse Even ts (AEs)........................................................................................ 42
4.3.2 Treatment E xposure ........................................................................................... 43
4.3.3 Dose Inten sity.................................................................................................... 45
4.3.4 Laboratory Data ................................................................................................. 46
4.3.5 ECGs ................................................................................................................. 46
4.3.6 Vital Signs ......................................................................................................... 47
4.3.7 General Consid erations for Safety Assessments ................................................. 47
4.4 Patient reported outcome.................................................................................... 50
4.4.1 EORTC QL Q-C30 ............................................................................................. 50
4.4.2 EORTC QLQ- H&N35 ....................................................................................... 53
4.6 Biomarker Variables .......................................................................................... 57
5. ANALYSIS M ETHODS .................................................................................... 57
5.1 General Principles.............................................................................................. 58
5.1.1 Multiple Testi ng Strateg y................................................................................... 60
5.2 Analysis Methods ............................................................................................... 61
5.2.1 Overall S urvival (OS) ........................................................................................ 61
5.2.2 Progression Free Survival (PFS) ........................................................................ 66
5.2.3 Ob jective Response Rate (ORR) ........................................................................ [ADDRESS_971966] Ob jective Response (BoR) ......................................................................... 66
5.2.5 Disease Control  Rate (D CR).............................................................................. 66
5.2.6 Duration of Re sponse (D oR).............................................................................. 67
5.2.7 Proportion of Patients Alive a nd Progression Free at 6 and 12 Months............... 67
5.2.8 Time to Respons e (TTR ).................................................................................... 67
5.2.9 Time from Rando mization to Sec ond Progression (PFS2) .................................. [ADDRESS_971967] and Sec ond Subsequent Therapy or 
Death ................................................................................................................. 67
5.2.11 Change in Tu mor Size........................................................................................ 67
5.2.12 Patient Reported Outcome (P RO)....................................................................... 68
[IP_ADDRESS] EORTC QL Q-C30 ............................................................................................. 68
[IP_ADDRESS] EORTC QLQ- H&N35 ....................................................................................... 69
[IP_ADDRESS] PRO Comp liance ............................................................................................... 70
5.2.13 Safety ................................................................................................................. 70
[IP_ADDRESS] Adverse Eve nts .................................................................................................. 70
[IP_ADDRESS] Laboratory A ssessmen ts..................................................................................... 75
[IP_ADDRESS] ECGs ................................................................................................................. 77
[IP_ADDRESS] Vital Signs ......................................................................................................... 77
5.2.14 WHO/ECOG Perfor mance Statu s....................................................................... 77
5.2.17 Demographic, Initial Diagnostics and Baseline Char acteristics  Data .................. 78
5.2.18 Treatment E xposure ........................................................................................... 79
5.2.19 Subsequent Therapy........................................................................................... 80
6. INTERIM ANALYSIS ...................................................................................... 80
7. CHANGES OF ANALYSIS FROM PROTOCOL ............................................. 81
8. REFERENCES .................................................................................................. 83
9. APPENDIX (NOT APPLICABLE) .................................................................... [ADDRESS_971968] OF TABLES
Table 1 Co-Primary Objectives .......................................................................... 15
Table 2 Secondary  Objectiv es............................................................................ 15
Table 3 Safety Objectives .................................................................................. 16
Table 5 Summary of Statistical Assumptions ..................................................... 24
Table 6 Summary of Outcome Var iables and Analysi s Populat ions.................... 25
Table 7 TL Visi t Respons es ............................................................................... 31
Table 8 NTL visit responses .............................................................................. 34
Table 9 Overall Visit Responses ........................................................................ 36
Table 10 Change from BL and Visit Response for EORTC QLQ C30 ................. 51
Table 11 Change from BL and Visit response for EORTC QLQ H&N35 ............. [ADDRESS_971969] OF FIGURES
Figure 1 Overall Study Design ............................................................................ 19
Figure 2 Study Flow Chart for MEDI4736 + Tremelimumab Combination 
Therapy and MEDI4736 M onotherapy Grou ps...................................... [ADDRESS_971970] Objective Response
CI Confidence Interval CR Complete ResponseCRA Clinical Research AssociateCRF / eCRF Case Report Form (electronic)CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed TomographyCTCAE Common Terminology Criteria for Adverse EventCTLA-4 Cytotoxic T–Lymphocyte-Associated Antigen 4CTM Clinical Team ManagerDBP Diastolic Blood PressureDCO Data Cut-OffDCR Disease Control Rate
DoR Duration of Response
ECG Electrocardiogram ECOG Eastern Cooperative Oncology GroupEDoR Expected Duration of ResponseEORTC European Organisation for Research and Treatment of Cancer
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_971971] Ratio
HRQoL Health-Related Quality of LifeIDMC Independent Data Monitoring CommitteeIMT Immunomodulatory TherapyIP Investigational ProductirRC Immune-Related Response Criteria
ITT Intent-to-Treat
IV IntravenousKM Kaplan-MeierMD Medical DoctorMedDRA Medical Dictionary for Regulatory ActivitiesMEDI4736 Immune-Mediated Therapymg Milli-gramMMA Medical Mon itoring Associate
MRI Magnetic Resonance Imaging
NA Not Applicable
nAb Neutralizing antibodyNCI National Cancer InstituteNE Not evaluableNED No evidence of diseaseNTL Non-target lesionsORR Objective response rateOS Overall survival
OS12 Proportion of patients alive at 12 months from randomization
OS18 Proportion of patients alive at 18 months from randomizationOS24 Proportion of patients alive at 24 months from randomizationPD Progressive diseasePD-1 Programmed cell death 1PD-L1 Programmed cell death ligand 1PD-L1 –ve Patients with PD-L1–negative tumor expression statusPD-L1 +ve Patients with PD-L1–positive tumor expression status
PDx Pharmacodynamic(s)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
10Abbreviation or 
special termExplanation
PFS Progression free survival
PR Partial response
PRO Patient reported outcomeq12W Every 12 weeksq2W Every 2 weeksq4W Every 4 weeks
QLQ-C30 v3 30-item core quality of life questionnaire, version 3
QLQ-H&N35 35-item head and neck quality of life questionnaireQoL Quality of lifeQTc QT interval corrected for heart rateQTcF QT interval corrected for heart rate using Fridericia's formulaRECIST 1.[ADDRESS_971972] Upper limit of normal
WHO World Health Organization
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
11AMENDMENT HISTORY
Date Brief description of change
24 May
2016In line with the Clinical Study Protocol (CSP) Amendments
!Changes in primary endpoints (OS instead of both OS and PFS)
!Removal of blinded independent central review
!Changes in multiple testing procedures
!Addition of an interim analysis
!Simplification of PRO endpoints for secondary analysis
!Text in sample size section updated
In line with project wide developments 
!Removal of non-critical sensitivity analyses 
!Removal of non-critical secondary analyses 
!Reduction of the lists of deviations regarded as important protocol deviations
!Change in definition for Total and Actual exposure.
!Removal of PID
!Addition of summaries of AESIs requiring concomitant medication and particularly 
the relationship of AESIs to the use of immunosuppressive agents
!Clarification of statistical method used to compute point estimate and confidence 
intervals for primary analysis
!Inclusion of additional prognostic factors, and changes in statistical methods for 
subgroup analyses
!Removal of formal analysis of Duration of Response endpoint
Other changes
!Addition of Time to response endpoint
!Additional minor clarifications.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
12Date Brief description of change
21
February 
2017In line with the Clinical Study Protocol (CSP) Amendment Version 5
!Changes from a single primary objective of MEDI4736 +tremelimumab versus SoC 
in terms of OS to co-primary objectives of MEDI4736 +tremelimumab versus SoC 
in terms of OS and MEDI4736 monotherapy versus SoC in terms of OS.
!Changes in multiple testing procedures.
!Text in sample size section updated.
In line with project wide developments 
!Hazard ratio and confidence interval derived at landmarks as per Klein’s method 
were removed.
!Description of haemorrhages adverse events added.
Other changes
!Addition of time to first and second subsequent therapy.
!Harmonization of PRO’s statistical analysis wording.
!Additional minor clarifications.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
13Date Brief description of change
5 January 
2018!The cut point for determining the PD-L1 positive and PD-L1 negative groups was 
confirmed to be 25%.
 
!Text defining what constitutes a suspected Hy’s law case has been clarified to show 
that ALT/AST elevations can be at any visit prior to, or at the same time as the
bilirubin elevation (i.e. do not have to be concurrent). 
!The method to control for tied observations in the statistical analyses has been 
specified along with the method fitting stratification variables (Efron and strata 
statements) to avoid ambiguity. 
!Wording stating confidence intervals would be (1- α)% simplified to 95%.
!Patients with high baseline PRO scores are excluded from analyses of time to 
deterioration. The threshold was changed from ≤95 to ≤90.   
!The definition of PFS2 has been updated to clarify that the second progression is the 
first progression following a first subsequent therapy. 
!The lab assessments to be included in the TFLs has been updated.
!The conversion from leukocyte percentages to counts has been added. 
!ECG text clarified to reflect that they’re collected ad hoc.
!“Subject too heavily affected by [CONTACT_713753]” added as a 
deterioration event for HRQoL.
!Text was added to section 4.3.7 to clarify the imputation rules for cases where there 
may be a missing AE start date.
!AESI list updated in section 4.3.1 to align with CSP amendment. 
!Table [ADDRESS_971973] of Care (SoC) therapeutic options, 
which only have transient and limited benefit (ORR: 4% to 13%, progression-free survival [PFS]: 2.5 months, and OS: 5.5 months) ( Shin and Khuri 2013 , Vermorken et al 2008 ). Thus, 
there is a significant unmet medical need for additional treatment options for use in this 
patient population.
Multiple lines of evidence suggest that SCCHN tumors, like many other malignancies, create 
a highly immunosuppressive environment and may be amenable to therapeutic intervention 
with immune-modulating agents. Two specific pathways, the programmed cell death ligand 1 (PD-1–PD-L1) axis and the Cytotoxic T–lymphocyte-associated antigen 4 (CTLA-4) pathway
have been successfully targeted by [CONTACT_713754][INVESTIGATOR_014] (IMT) to obtain tumor 
reduction.
MEDI4736, an antibody that blocks the interacti on between PD-L1 and its receptors, may 
relieve PD-L1-dependent immunosuppressive effects and, therefore, enhance the cytotoxic 
activity of anti-tumor T- cells. This hypothesis is supported by [CONTACT_713755] d ata from 
Study 1108 which indicates encouraging response rates (RRs), duration of response (DoR), 
and radiographic tumor shrinkage in [ADDRESS_971974] additive or synergistic activity ( Pardoll 2012 ), resulting in higher RRs in SCCHN. 
Evidence of clinical activity and manageable safety profile has been observed in Study 
D4190C00006. 
The co-primary objectives of the study are:
!To assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC
in patients with squamous cell carcinoma of the head and neck (SCCHN), regardless of programmed cell death ligand 1 (PD-L1) status, in terms of overall survival (OS)
!To assess the efficacy of MEDI4736 monotherapy versus SoC in patients with SCCHN, 
regardless of PD-L1 status, in terms of overall survival (OS)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
152. STUDY OBJECTIVES
2.1 Co-Primary Objectives
Table 1 Co-Primary Objectives
Co-primary Objectives: Outcome Measures:
To assess the efficacy of MEDI4736 + tremelimumab 
combination therapy versus SoC in terms of OSOS in all patients, regardless of PD-L1 
status
To assess the efficacy of MEDI4736 monotherapy versus
SoC in terms of OSOS in all patients, regardless of PD-L1 
status
OS Overall survival; PD-L1 programmed cell death ligand 1; SoC Standard of Care.
2.1.1 Secondary Objectives
Table 2 Secondary Objectives
Key Secondary Objectives: Outcome Measures:
To further assess the efficacy of MEDI4736 + 
tremelimumab combination therapy versus 
SoC in terms of OSOS in PD-L1-negative patients
To assess the efficacy of MEDI4736 
monotherapy versus SoC in terms of OSOS in PD-L1-positive patients
To further assess the efficacy of MEDI4736 + 
tremelimumab combination therapy and MEDI4736 monotherapy versus SoC in terms 
of PFS, PFS2, ORR, TTR, TFST, TSST, DoR, DCR, APF6, APF12, OS12, OS18, and OS24PFS, PFS2, ORR, TTR, DoR, DCR, APF6, and 
APF12 using the site Investigator’s assessments 
according to RECIST 1.[ADDRESS_971975]
To assess the efficacy of MEDI4736 + 
tremelimumab combination therapy compared 
to MEDI4736 monotherapy in terms of PFS, ORR, and OSPFS and ORR in PD-L1–negative patients using the 
site Investigator’s assessments according to RECIST 1.1
OS in PD-L1–negative patients
To explore symptoms and HRQoL in patients 
treated with MEDI4736 + tremelimumab 
combination therapy and MEDI4736 monotherapy versus SoC using the EORTC 
QLQ-C30 v3 and the H&N35 moduleEORTC QLQ-C30: global health QoL, functioning 
(physical), and symptoms (fatigue)
EORTC QLQ-H&N35: symptoms (pain, swallowing)
Changes in World Health Organization/Eastern 
Cooperative Oncology Group performance status
APF6 P roportion of patients alive and progression free at 6 months from randomization; APF12 Proportion of patients alive and prog ression 
free at 12 months from randomization; DCR Disease control rate; Do R Duration of response; EORTC European Organisation for Research 
and Treatment of Cancer; QLQ-C30 v3 30-item core quality of life questionnaire, version 3; H&N35 35-item head and neck quality of  life 
questionnaire; HRQoL H ealth-related qu ality of life; OS12 Overall survival at 12 months; OS18 Overall survival at 18 months; OS24 O verall 
survival at 24 months; PD-L1 programmed cell death ligand 1; PFS Progre ssion-free survival; PFS2 Time from randomization to secon d 
PFS; QoL Quality of life; RECIST 1.1 Response Evaluation Criteria in Solid Tumors version; SoC Standard of Care; TTR Time to treatme nt 
response; TFST Time to first subsequent therapy; TSST Time to second subsequent therapy
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
162.1.2 Safety Objectives
Table 3 Safety Objectives
Safety Objective: Outcome Measures:
To assess the safety and tolerability profile of 
MEDI4736 + tremelimumab combination therapy 
and MEDI4736 monotherapy compared to SoCAEs, physical examinations, laboratory findings, 
and vital signs
AE adverse event; SoC Standard of Care
  
 
 
 
  
 
  
 
  
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
17 
 
  
 
 
 
 
  
 
 
2.2 Study Design
This is a randomized, open-label, multi-cen ter, global Phase III study to determine the 
efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 
monotherapy versus SoC therapy in the treatment of patients with recurrent or metastatic 
SCCHN who have progressed during or after only one palliative systemic treatment regimen 
for recurrent or metastatic disease that must ha ve contained a platinum agent or who have 
progressed within [ADDRESS_971976] dose of platinum given as part of multimodality therapy 
of curative intent (i.e., those who are refractory to prior platinum therapy).
Patients will undergo a screening assessment on their tumor tissue sample to determine HPV 
status (for patients with oropharyngeal cancer only). 
Inclusion criteria include a valid PD-L1 result.  PD-L1 expression levels are assessed by [CONTACT_713756]-L1 (SP263) Assay.  PD-L1 positive is defined as ≥25% of tumor 
cells with membrane staining for PD -L1 at any intensity.  PD-L1 low/negative is defined as 
<25% of tumor cells with membrane staining for PD-L1 at any intensity.
If the patient’s PD-L1 status has already been assessed using the VENTANA PD-L1 SP263 
IHC assay as a part of the screening process for another [COMPANY_008]/ MedImmune study, this 
test result can be used for the determinatio n of eligibility. The sp ecified expre ssion cu t-off 
level will be used for the purpose of stratification and therefore included in the stratified log 
rank tests for OS.  However the actual cut-off level for the subgroup analyses of OS by [CONTACT_4002]-L1 
status and also as the basis for determining the PD-L1-negative subgroup in the MTP might be done using different cutoff (see sections 3.1.2 and 3.1.3 ).
Patients will be randomized in a stratified manner according to prognostic factors: PD-L1 
status, tumor location/HPV status, and smoking status.  HPV status and smoking status are 
known prognostic markers for patients with head and neck cancer.  Patients will be 
randomized in a 1:1:1 ratio to receive treatment with MEDI4736 monotherapy, MEDI4736 + 
tremelimumab combination therapy, or SoC therapy.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
18Patients in the MEDI4736 monotherapy tr eatment group will receive 10 mg/kg MEDI4736 via 
intravenous (IV) infusion q2w until PD. Patients in the MEDI4736 + tremelimumab treatment 
group will receive 20 mg/kg MEDI4736 via IV i nfusion q4w for up to 4 months and 
tremelimumab 1 mg/kg via IV infusion q4w for 4 months.  Upon completion of 4 months of combination therapy, patients in the MEDI4736 + tremelimumab arm will then continue 
dosing with MEDI4736 monotherapy at 10 mg/kg q2w beginning [ADDRESS_971977] dose
of combination therapy is administered until PD.  Patients in the SoC treatment group will receive monotherapy with 1 of the following therapi[INVESTIGATOR_713737]’s discretion until 
PD: cetuximab, a taxane (i.e., docetaxel or paclitaxel), methotrexate, or a fluoropyrimidine 
(i.e., 5-FU, TS-1, or capecitabine).
Patients randomized to 1 of the IMT treatment groups will receive treatment with either 
MEDI4736 or MEDI4736 + tremelimumab beginning on Day [ADDRESS_971978] 1.1. (unless, in  the Investigator’s opi[INVESTIGATOR_1649], the patient 
continues to receive benefit from the treatment ), initiation of alternative cancer therapy, 
unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
Patients with PD who, in the Investigator’s opi[INVESTIGATOR_1649], continue to receive benefit from their assigned IMT treatment and who meet the criteria for treatment in the setting of PD may 
continue to receive their assigned IMT treatment after consultation with the Sponsor and at the 
Investigator’s discretion.  All patients randomized to [ADDRESS_971979] 1.1. Patients with confirmed 
progression in the monotherapy arm or in the combination portion of therapy in the 
MEDI4736 + tremelimumab arm cannot continue therapy if the progression occurred during 
dosing after objective response in the target lesions (i.e., the response and progression events 
both occurred while receiving active IP during the same treatment period in the target lesions).  
Patients who the Investigator determines may not continue IMT treatment after PD will enter 
follow-up and will be followed up until death.  Patients who have discontinued IMT treatment 
due to toxicity or symptomatic deterioration, those who have no objective disease progression according to RECIST 1.1, or who have commenced subsequent anticancer therapy, will be 
followed up until death.
Patients randomized to the SoC arm will receive the Investigator-chosen SoC treatment 
beginning on Day 0 until PD, initiation of alter native cancer therapy, unacceptable toxicity, 
withdrawal of consent, or another discontinuation criterion is met.  For equivocal findings of 
progression (e.g., very small and uncertain new lesions; cystic changes or necrosis in existing 
lesions), treatment may continue until the next scheduled assessment.  All patients randomized 
to the SoC treatment group require documentation of objective disease progression according 
to RECIST 1.1. A second scan obtained at a minimum of [ADDRESS_971980] commenced subsequent 
anticancer therapy, will be followed up for study endpoints (objective disease progression 
according to RECIST 1.1 or death).
Tumor assessments will be performed using computed tomography (CT) or magnetic 
resonance imaging (MRI) at the times specified in the protocol.  (tables 2 and 3). RECIST 1.1 
measurements as given by [CONTACT_9257]’s assessments will be used to derive the 
secondary variables of PFS, ORR, DoR, DCR, APF6, and APF12.
Below is a schematic diagram of the overall study design ( Figure 1 ).  A flow chart for the IMT 
treatment groups (MEDI4736 monotherapy and MEDI4736 + tremelimumab combination therapy) is presented in Figure 2 , followed by a flow chart for the SoC group which is 
presented in Figure 3 . 
Figure 1 Overall Study Design
Note: For all Standard of Care therapi[INVESTIGATOR_014], a particular treatment (cetuximab, taxane, methotrexate, or 
fluoropyrimidine-based regimen) will not be used in patients who have previously received that treatment 
for recurrent/metastatic disease or who have experienced recurrence or progression of disease within 
6 months of prior multimodal therapy using that particular treatment.
*:  For HPV status, only patients with oropharyngeal cancer will be tested. 
HPV human papi[INVESTIGATOR_28597]; PD-L1 programmed cell death ligand 1; OS overall survival; SCCHN Squamous 
Cell Carcinoma of the Head and Neck.

Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
20Figure 2 Study Flow Chart for MEDI4736 + Tremelimumab Combination 
Therapy and MEDI4736 Monotherapy Groups
Follow-up assessments (Table 4 or Table 5 of the protocol)Screening visit to complete eligibility
(Day -28 to -1)a
Day 0: First day of treatment for eligible patients
Treatment period
(MEDI4736 + tremelimumab or MEDI4736) - assessments per Table [ADDRESS_971981] 1.1 performed at Screening, then every 8 weeks thereafter 
(relative to the date of randomization) until objective disease progressionb
Disease control after the 
initial 4-month combination 
therapy portion of treatment 
followed by [CONTACT_713757]4736 monotherapy 
portion (MEDI4736 + 
tremelimumab arm only)cDiscontinuation 
of treatment
Due to reasons 
other than 
objective 
disease 
progressionbDue to 
objective 
disease 
progressionb
Continue tumor assessment 
using RECIST 1.1 until objective 
disease progression or other 
discontinuation criterionb,c
Objective disease 
progressionb,dRetreatment
MEDI4736 + 
Tremelimumab –
Assessments per Table 
2eof the protocolTreatment 
through PD
Discontinuation 
of treatment
Discontinuation 
of treatment
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_971982] occur within 
28 days of all procedures (with the exception of tumor biopsy [if required] and PD-L1 testing) used for screening 
purposes.  If the patient’s PD-L1 status has already been assessed using the VENTANAPD-L1 (SP263) IHC assay as a 
part of the screening process for another [COMPANY_008]/MedImmune study, this test result can be used for the 
determination of eligibility.
bA confirmatory scan is required following the initial demonstration of PD, if clinically feasible.     A second scan 
obtained at a minimum of [ADDRESS_971983] 1.1. Administration of 
IMT treatment will continue between the initial assessment of progression and confirmation for progression.  Patients in 
the IMT treatment groups with confirmed PD who continue to receive study treatment at the discretion of the 
Investigator (following consultation with the Sponsor) will continue to follow the assessments in Table [ADDRESS_971984] 
any significant, unacceptable, or irreversible toxicities that indicate that continuing treatment will not further benefit the patient, and that the patient still meets all of the inclusion criteria and none of the exclusion criteria for this study including re-consenting to continue treatment.  Patients with rapid tumor progression or with symptomatic progression 
that requires urgent medical intervention (e.g., central nervous system metastasis, respi[INVESTIGATOR_90860], or spi[INVESTIGATOR_13377]) will not be eligible to continue to receive IP.
cPatients assigned to the MEDI4736 + tremelimumab comb ination therapy arm who complete the 4 cycles of the 
combination therapy portion of the treatment regimen that achieve and maintain disease control (i.e., CR, PR, or SD) 
and subsequently progress on monotherapy MEDI4736 may restart their assigned treatment once Before restarting 
MEDI4736 + tremelimumab combination treatment, the Investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicities that indicate that continuing treatment will not further benefit the 
patient, and that the patient still meets all of the inclusion criteria and none of the exclusion criteria for this study 
including re-consenting to restart treatment. To restart study treatment, the patient must not have received an 
intervening cancer therapy post study treatment discontinuation. Patients should have a baseline tumor assessment within 28 days of restarting study treatment; all further scans should occur q8w (relative to the date of restarting study 
treatment). Patients cannot obtain retreatment if the progression occurred during dosing with the combination portion of 
therapy after objective response in the target lesions (i.e., the response and progression events both occurred while receiving active IP during the same treatment period in the target lesions). Retreatment in the combination arm can only 
occur if PD occurs during the monotherapy portion of dosing.
dPatients with objective disease progression according to RECIST 1.[ADDRESS_971985] scans conducted 
according to local practice until the patient commences a new treatment (these scans are optional).
ePatients who progress on the MEDI4736 + tremelimumab arm may be eligible for retreatment if they progress during 
the monotherapy portion of dosing.
CR Complete response; IP Investigational product; PD Progressive disease; PD-L1 Programmed cell death ligand-1; 
PR Partial response; q8w Every 8 weeks; RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1; 
SD Stable disease.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_971986] occur within 
28 days of all procedures (with the exception of tumor biopsy [if required] and PD-L1 testing) used for screening 
purposes.  If the patient’s PD-L1 status has already been assessed using the VENTANAPD-L1 (SP263) IHC assay as a 
part of the screening process for another [COMPANY_008]/MedImmune study, this test result can be used for the 
determination of eligibility. 
bA confirmatory scan is required if clinically feasible following the initial demonstration of PD. A second scan obtained 
at a minimum of 4 weeks later to confirm progression is required for treatment management decisions only and only 
where it is clinically feasible. This scan should occur preferably at the next scheduled visit and no earlier than 4 weeks 
after the initial assessment of PD in the absence of clinical deterioration if clinically feasible. For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes or necrosis in existing lesions), treatment may 
continue until the next scheduled assessment. Disease response assessment should be solely based on RECIST 1.[ADDRESS_971987] 1.1. In the SoC group, it 
is at the Investigator’s discretion whether or not a patient with uncertain PD continues treatment until PD is confirmed; 
however, a scan with objective disease progression according to RECIST 1.[ADDRESS_971988] scans 
conducted according to local practice until the patient commences a new treatment (these scans are optional).Screening visit: Screening Assessments
(Day -28 to -1)a
Day 0: First day of treatment for eli gible patients
Treatment period
(Standard of Care) - assessments per Table [ADDRESS_971989] 1.1 performed at Screening, then every 8 weeks thereafter 
(relative to randomization) until ob jective disease progressionb
Discontinuation of treatment
Due to reasons other than 
objective disease progressionbDue to objective disease 
progressionb
Continue tumor assessment using RECIST 1.1 until objective disease 
progression or other discontinuation criterionb,c
Objective disease progression or other 
discontinuation criterionb,c
Follow-up assessments (Table 4 or Table 5 of the protocol)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
232.3 Number of Patients
The sample size for this study was selected to be consistent with the research hypothesis as 
described in Section 8.5 of the Clinical Study Protocol (CSP).
The study will enroll approximately [ADDRESS_971990] dose of platinum given as 
part of multimodality therapy with curative in tent.   Patients will be randomized in a 1:1:1 
fashion to MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or 
SoC (240 patients in each treatment group).  An approximate 40% attrition rate due to screen failures and a <2% attrition rate due to wit hdrawals during treatment are expected. The study 
is sized to characterize the OS benefit of MEDI4736 + tremelimumab combination therapy 
versus SoC in all patients, regardless of PD-L1 status and to characterize the OS benefit of MEDI4736 monotherapy versus SoC in all patien ts, regardless of PD-L1 status.  The sizing 
assumes a 3-month delay in separation of the survival curves between each arm, hence the use 
of average hazard ratios (HRs).
The analysis of OS is expected to be performed after approximately 11 months of follow-up:
!When [ADDRESS_971991] occurred in 480 patients (78% maturity) across the 
MEDI4736 + tremelimumab combination therapy and SoC arms, regardless of PD-L1 status AND
!When [ADDRESS_971992] occurred in 480 patients (78% maturity) across the 
MEDI4736 monotherapy and SoC arms, regardless of PD-L1 status.
Interim analysis for OS will be performed when a total of 300 events (80% of required events) 
have been accumulated across the MEDI4736 + tremelimumab combination therapy and SoC 
arms, regardless of PD-L1 status and a total of 300 events (80% of required events) have been 
accumulated across the MEDI4736 monotherapy a nd SoC arms, regardless of PD-L1 status. 
MEDI4736 + tremelimumab combination therapy or MEDI4736 monotherapy, in all 
patients, regardless of PD-L1 status (co-primary objectives)
If OS at 18 months was 25% with either the MEDI4736 + tremelimumab combination therapy 
orMEDI4736 monotherapy and 10% with SoC (w ith 5.5 month median OS), and assuming 
the true average OS HR is 0.69, the study will have 90% power to demonstrate statistical 
significance at the 2.2% level (using a 2-sided test) for the comparison of either MEDI4736 + tremelimumab combination therapy orMEDI4736 monotherapy versus SoC, allowing for 
1 interim analysis conducted at approximately 80% of the target events with the smallest 
treatment difference that could be statist ically si gnificant being an average HR of 0.79.  With 
an assumed 15-month recruitment period and a minimum follow-up period of 11 months from 
“last patient in”, it is anticipated that the fin al analysis will be performed [ADDRESS_971993] patient has been recruited.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
24MEDI4736 + tremelimumab combination therapy in PD-L1-negative patients (key 
secondary objective)
Assuming 70% of randomized patients are PD-L1-negative patients (i.e., 504 PD-L1-negative 
patients with 168 in each treatment arm), and if OS at 18 months was 28% with the 
MEDI4736 + tremelimumab combination therapy and 10% with SoC (with 5.5 month median 
OS), and assuming the true average OS HR is 0.64, the study will have 90% power to demonstrate statistical significance at the 2.2% level (using a 2-sided test) for the comparison 
of MEDI4736 + tremelimumab combination therapy versus SoC in the PD-L1-negative 
patients, with the smallest treatment difference that could be statistically significant being an 
average HR of 0.75.  With a 15-month recruitment period and a minimum follow-up period of 
[ADDRESS_971994] patient has been recruited. 
MEDI4736 monotherapy in PD-L1-positive patients (other secondary objective)
Assuming 30% of randomized patients are PD-L1-positive patients (i.e., 216 PD-L1-positive 
patients with 72 in each treatment arm), and if OS at 18 months was 41% with either MEDI4736 monotherapy and 10% with SoC (with 5.5 month median OS), and assuming the 
true average OS HR is 0.49, the trial will have 90% power to demonstrate statistical 
significance at the 2.5% level (using a 2-sided test) for the comparison of either MEDI4736 monotherapy versus SoC in PD-L1 positive patients, with the smallest treatment difference 
that could be statistically significant being an average HR of 0.63.  With a 15-month 
recruitment period and a minimum follow-up period of [ADDRESS_971995] patient has been recruited. A
summary of the statistical assumptions is provided in Table 5 .
Table 5 Summary of Statistical Assumptions
N Overall 
HRLandmarksaEvents 
(maturity)Power Critical values
HR (Landmarks)
MEDI4736 + tremelimumab combination therapy versus SoC
All patients, regardless 
of PD-L1 status480 0.69 10 vs. 25% 375 (78%) 90% 0.79 (10 vs. 19%)
PD-L1–negative 336 0.64 10 vs . 28% 258 (77%) 90% 0.76 (10 vs. 21%)
MEDI4736 monotherapy versus SoCAll patients, regardless 
of PD-L1 status480 0.69 10 vs. 25% 375 (78%) 90% 0.79 (10 vs. 19%)
PD-L1–positive 144 0.49 10 vs. 41% 102 (71%) 90% 0.63 (10 vs. 28%)
aOS landmark is 18 months; the assumed recru itment and minimum follow-up periods for all patients, 
regardless of PD-L1 status, are 15 and 11 months, respectively (i.e., 26-month study duration); Sample size 
estimate in the PD-L1 negative comparison assume that 70% of the patients enrolled have PD-L1 negative 
disease. Sample size estimate in the PD-L1 positive comparison assume that 30% of the patients enrolled have PD-L1 positive disease.
HR hazard rate; PD-L1 programmed cell death ligand 1; SoC Standard of Care
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
253. ANALYSIS SETS
3.1 Definition of Analysis Sets
Four analysis sets are defined for this study. Table 6 gives a summary of outcome variables 
and analysis populations.
3.1.1 Full Analysis Set (FAS)
The full analysis set (FAS) will include all randomized patients.  The FAS will be used for all 
efficacy analyses (including PROs).  Treatment groups will be compared on the basis of randomized study treatment, regardless of the treatment actually received.  Patients who were 
randomized but did not subsequently go on to receive study treatment are included in the 
analysis in the treatment group to  which they were ra ndomized.
3.1.2 PD-L1-Negative Analysis Set
The PD-L1-negative analysis set will include the subset of patients in the FAS whose PD-L1 
status is PD-L1-negative as defined by [CONTACT_713758]-L1 (SP263) IHC assay. The cut-
off level to determine the PD-L1-negative analysis set w ill be the s ame as that for 
stratification purposes (<25% PD ‑L1–membrane expression in tumor tissue).
3.1.3 PD-L1-Positive Analysis Set
The PD-L1-positive analysis set will include the subset of patients in the FAS whose PD-L1 
status is PD-L1-positive as defined by [CONTACT_713758]-L1 (SP263) IHC assay. The cut- off 
level to determine the PD-L1-positive analysis set will be the same as that for stratification 
purposes (>25% PD ‑L1–membrane expression in tumor tissue). 
3.1.4 Safety Analysis Set
The Safety Analysis Set (SAS) will consist of all patients who received at least 1 dose of study 
treatment.  Safety data will not be formally analyzed but summarized using the safety analysis set according to the treatment received, that is , erroneously treated patients (e.g., those 
randomized to treatment A but actually given treatment B) will be summarized according to 
the treatment they actually received.
 
Table 6 Summary of Outcome Variables and Analysis Populations
Outcome variable Population
Efficacy data
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
26Table 6 Summary of Outcome Variables and Analysis Populations
Outcome variable Population
OS Full analysis set (ITT population)
PFS, PFS2, ORR, TTR, TFST, TSST, DoR, DCR, AFP6, 
APF12, OS12, OS18, OS24, PROs, and symptom endpointsFull analysis set (ITT population)
OS, PFS, ORR, TTR, PD-L1-negative analysis set
OS, PFS, ORR, TTR, PD-L1-positive analysis set
Demography Full analysis set (ITT population)
EORTC QLQ-C30 and H&N35 Full analysis set
Safety Data
Exposure Safety analysis setAEs Safety analysis setLaboratory measurements Safety analysis set
WHO performance status Safety analysis set
Vital signs Safety analysis set
AE Adverse event; APF6(12) Proportion of patients alive and progression free at 6 (12) months; DoR Duration 
of response; ITT Intent-to-Treat; ORR Objective res ponse rate; OS Overall survival; OS12(18, 24) Proportion of 
patients alive at 12 (18, 24) months after randomization; PD-L1 Programmed cell death ligand 1; PFS Progression-free survival; PFS2 Second progression;  PRO Patient-reported outcome; TTR Time to response; TFST Time to first subsequent therapy; TSST Time to second subsequent therapy
3.[ADDRESS_971996]-entry deviations are deviations from the 
protocol that occurred after the p atient was randomized to the study.
The deviations below will be programmatically derived. The following general categories will be considered important deviations and be listed and 
discussed in the Clinical Study Report (CSR) as appropriate for the study.
!Patients who deviate from key entry criteria (Deviation 1). These are inclusion criteria 3, 
4, 6, 8 and exclusion criteria 1, 7, 9 as per clinical study protocol D4193C00002, fifth edition, dated 07SEP2016.
- Inclusion criteria:
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
273) Histologically or cytologically confirmed recurrent or metastatic SCCHN (oral 
cavity, oropharynx, hypopharynx, or larynx) not amenable to therapy with curative 
intent (surgery or radiation therapy with  or without chemotherapy). Patients who 
refuse radical resection are eligible.
4) Tumor progression or recurrence during or after only one palliative systemic 
treatment regimen for recurrent or metastatic disease that must have contained a platinum agent OR progression within [ADDRESS_971997] dose completion of 
platinum given as part of containing multimodality therapy with curative intent.
6) Confirmed PD-L1-positive or -negativ e SCCHN by [CONTACT_713758]-L1 (SP263) 
IHC assay on newly acquired tumor tissue (preferred) or archival tissue ( ≤3 years old).
- If the patient’s PD-L1 status has already been assessed using the VENTANA PD-
L1 (SP263) IHC assay as a part of the screening process for another [COMPANY_008]/MedImmune study, this test result can be used for the determination of 
eligibility, provided the PD-L1 s tatus was obtained on tissue within the last 3 years.
- Note: A positive PD-L1 sample is measured using a defined cut-off based on 
≥25% of tumor cells with membrane staining of any intensity for PD-L1. A 
negative PD-L1 sample is defined as <25% of tumor cells with membrane staining 
for PD-L1.
8) At least 1 lesion, not previously irradiated, that can be accurately measured at 
baseline as ≥[ADDRESS_971998] diameter (except lymph nodes which must have a 
short axis ≥15 mm) with CT or MRI and that is suitable for accurate repeated 
measurements as per RECIST 1.1 guidelines. Lesions in a previously irradiated field 
can be used as measurable disease provided that there has been demonstrated 
progression in the lesion.
- Exclusion criteria:
1) Histologically or cytologically confirmed squamous cell carcinoma of any other 
primary anatomic lo cation in the head and neck not sp ecified in the inclusion criteria, 
patients with SCCHN of unknown primary, and non-squamous histologies (e.g., 
nasopharynx or salivary gland).
7) Current or prior use of immunosuppressive medication within [ADDRESS_971999] dose of their assigned IP. The following are exceptions to this criterion:
-Intranasal, inhaled, topi[INVESTIGATOR_8826], or local steroid injections (e.g., intra-articular 
injection)
-Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of 
prednisone or its equivalent
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
28-Steroids as pre-medication for hypersensitivity r eactions (e.g., CT scan pre-
medication)
9) Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease, diverticulitis  with the exception of a prior epi[INVESTIGATOR_713738], celiac disease, or other serious GI chronic conditions 
associated with diarrhea; systemic lupus erythematosus; Wegener syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves’ disease; rheumatoid 
arthritis; hypophysitis; uveitis, etc.) within the past 3 years prior to the start of 
treatment. The following are exceptions to this criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement or any skin condition not requiring systemic treatment
!Baseline RECIST scan > 40 days before randomization (Deviation 2). Note that although 
the screening period for baseline RECIST assessment was [ADDRESS_972000] assessments of greater than 40 days 
will be deemed as constituting an important deviation.
!No baseline RECIST 1.1 assessment on or before date of rando mization (Deviation 3).
!Received prohibited systemic anti-cancer agents (Deviation 4). Please refer to the CSP 
section 7.7 for the systemic anti-cancer agents that are detailed as being ‘excluded’ from permitted use during the study. This will be used as a guiding principle for the physician review prior to database lock.
In addition to the programmatic determination of the deviations above, monitoring notes or 
summaries will be reviewed to determine any im portant post entry deviations that are not 
identifiable via programming, and to check that those identified via programming are correctly 
classified. The final classification will be made prior to database lock.  For example, details of 
disallowed concomitant medication use w ill be reviewed by a physician and may be 
determined as key.
4. PRIMARY AND SECONDARY VARIABLES
4.[ADDRESS_972001] version 1.1 (see further Appendix F of the CSP) tumor response 
data will be used to determine each patient’s visit response.  It will also be used to determine 
if and when a patient has progressed and also their best objective response.  RECIST 1.[ADDRESS_972002]/MRI assessments of the neck (from base of skull) 
through the chest and abdomen (including liver).  Additional anatomy s hould be imaged based 
on signs and symptoms of individual patients at baseline and follow-up.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
29The baseline assessments should be performed no more than 28 days before start of study 
treatment and ideally should be performed as close as possible to the start of study treatment
(Tables 2 and 3 of CSP). Follow-up assessments will be performed every [ADDRESS_972003] 
48 weeks (relative to the date of rando mization) a nd then every 12 weeks as ind icated in the 
schedule of procedures presented in the protocol (Tables 2 to 5 of CSP). Follow-up 
assessments will be performed every [ADDRESS_972004] 48 weeks (relative to the date of 
randomization) and then every 12 weeks as indicated in the schedule of procedures presented 
in the protocol (Tables 2 to 5 of CSP) until confirmed objective disease progression per 
RECIST 1.1.  The confirmatory scans should preferably be performed at the next scheduled 
visit (relative to the date of rando mization) and no less than 4 weeks after the initial 
assessment of PD (in the absence of clinically significant deterioration) and prior to initiation 
of alternate therapy. Confirmation of progressi on in patients in the SOC arm is preferable and 
should be done if clinically feasible. If an unscheduled assessment was performed and the 
patient has not progressed, ev ery attempt should be made to perform the subsequent 
assessments at their scheduled visits (relative to the date of randomization).  All confirmatory 
scans should be recorded on the database.
Progression would be considered confirmed if the following criteria are met:
!≥20% increase in the sum of diameters of target le sions (TL) compared with the nadir at 
2 consecutive visits with an absolute increase of 5 mm.
!The assessment of progression of ≥20% increase in the sum diameters of target lesions 
compared with the nadir is at the first progression time point relative to the nadir (the smallest sum of diameters and this may be at baseline or subsequent follow-up visit). The confirmed scan confirms the persistence of the ≥20% increase relative to the nadir.
!And/or significant progression (worsening) of non -target lesions (NTL) or new lesions at 
the confirmatory PD time point compared with  the first time point where progression of 
non-target lesions or new lesions identified.
!And/or additional new unequivocal lesions at the confirmatory PD time point compared 
with the first time point new lesions were identified.
In the absence of significant clinical deterioratio n, the investigator should continue IMT 
treatment until progression is c onfirmed. If progression is not confirmed, then the patient 
should continue on IMT treatment and on treatment assessments. Treatment through PD in the 
Standard of Care group is at the Investigator’s discretion; however, a confirmatory scan is 
required for all patients in the Standard of Care group even if a subsequent treatment is 
started.
If a patient discontinues treatment (and/or receives a subsequent cancer therapy) prior to 
progression, then the patient should still continue to be followed until confirmed objective 
disease progression.
IMT Treatment groups
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972005] scans every 8 week s while on treatment (relative to the date of 
randomization) until study tr eatment is stopped.  Patients with rapid tumor progression or with 
symptomatic progression that requires urgent medi cal intervention (e.g., central nervous 
system metastasis, respi[INVESTIGATOR_713739], or spi[INVESTIGATOR_13377]) 
will not be eligible to continue to receive study treatment. IP s hould be discontinued if there is 
confirmed PD while receiving IMT following a previous response (CR or PR) to IP in the 
target lesions (i.e., the response and progression events both occurred while receiving active 
IP during the same treatment period in the target lesions).
RECIST outcomes will be calculated using a computer program for site investigator data.  
4.1.[ADDRESS_972006] 1.1 visit response of CR, 
PR, SD, or PD depending on the status of their disease compared with baseline and previous assessments.  Baseline will be assessed within the 28 days prior to randomization.  If a patient 
has had a tumor assessment that cannot be evaluated, then the patient will be assigned a visit 
response of not evaluable (NE, unless there is objective disease progression according to RECIST 1.1 in which case the response will be assigned as PD).  Imaging and procedures 
performed before signing the ICF may be used for screening purposes if the patient consents.
[IP_ADDRESS] Site Investigator Assessment Using RECIST 1.1: Target Lesions (TLs)
Measurable disease is defined as having at least one measurable lesion, not previously 
irradiated, which is ≥ [ADDRESS_972007] diameter (except lymph nodes which must have 
short axis ≥ 15 mm) with CT or MRI and which is suitable for accurate repeated 
measurements.
A patient can have a maximum of 5 measurable lesions recorded at baseline with a maximum 
of 2 lesions per organ (representative of all lesions involved suitable for accurate repeated 
measurement) and these are referred to as target lesions (TLs).  If more than one baseline scan 
is recorded, then measurements from the one that has the latest date prior to and including
randomization w ill be used to define the baseline sum of TLs.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion, which can be measured reproducibly, should be selected.
All other lesions (or sites of disease) not recorded as TL should be identified as NTL at 
baseline.  Measurements are not required for these lesions, but their status should be followed 
at subsequent visits.
Measurable disease (i.e. at least one TL) is one of  the entry criteria for the study. However, if 
a patient with non-measurable disease is enrolled in the study, the evaluation of overall visit 
responses will be based on the overall NTL assessment and the absence/presence of new 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
31lesions (see Section [IP_ADDRESS] for further details).  If a patient does not have measurable disease 
at baseline, then the TL visit response will be not applicable (NA).  
Table 7 TL Visit Responses
Visit Responses Description
Complete Response (CR) Disappearance of all target lesions since baseline.  Any pathological 
lymph nodes selected as target lesions must have a reduction in short axis 
to <10 mm.
Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD
Not Evaluable (NE) Only relevant in certain situations (i.e. if any of the target lesions were not 
assessed or not evaluable or had a lesion intervention at this visit; and 
scaling up could not be performed for lesions with interventions). Note: If the sum of diameters meets the progressive disease criteria, progressive disease overrides not evaluable as a target lesion response
Not Applicable (NA) No target lesions are recorded at baseline
Rounding of TL data
For calculation of PD and PR for TLs, percentage changes from baseline and previous 
minimum should be rounded to [ADDRESS_972008] before assigning a TL response.  For example,
19.95% should be rounded to 20.0% but 19.94% should be rounded to 19.9%
Missing TL data 
For a visit to be evaluable, all TL measurements should be recorded.  However, a visit 
response of PD should st ill be assigned if any of the following occ urred:
!A new lesion is recorded.
!A NTL visit response of PD is recorded.
!The sum of TLs is sufficiently increased to result in a 20% increase, and an absolute 
increase of ≥ 5mm, from nadir even assuming the non-recorded TLs have disappeared.
Note: the nadir can only be taken from asse ssments where all the TLs had a lesion diameter 
recorded.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
32Lymph nodes
For lymph nodes, if the size reduces to < [ADDRESS_972009] ill be used to determine the TL visit 
response as normal.  In the special case where all lymph nodes are < 10 mm and all other TLs 
are 0 mm then although the sum may be >[ADDRESS_972010] be applied:
!Step 1:  If all lesions meet the CR criteria (i.e. 0 mm or < 10 mm for lymph nodes) then 
response will be set to CR irrespective of whether the criteria for PD of TL is also met i.e. if a lymph node LD increases by 20% but remains < 10 mm. 
!Step 2:  If some lesion measurements are missing but all other lesions meet the CR criteria 
(i.e. 0 mm or < 10 mm for lymph nodes) then response will be set to NE irrespective of 
whether when referencing the sum of TL diameters, the criteria for PD is also met. 
!Step 3:  If not all lesions meet the CR criteria and the sum of lesions meets the criteria for 
PD then response will be set to PD
!Step 4:  If after steps 1 – 3 a response can still not be determined the response will be set 
to remain as CR
TL too large to measure
If a TL becomes too big to measure this should be indicated in the database and a size (‘x’) 
above which it cannot be accurately measured should be recorded.  If using a value of x in the calculation of TL response would not give an over all visit response of PD, then this will be 
flagged and reviewed by [CONTACT_3476].  It is exp ected that a visit response of PD will remain 
in the vast majority of cases.  
TL too small to measure
If a TL becomes too small to measure a value of [ADDRESS_972011] has indicated and entered a smaller value that can be reliably measured.  If a TL response of PD results, then this will be reviewed by [CONTACT_58860].
Lesion intervention
Any TL (including lymph nodes), which has had intervention during the study (for example, 
radiotherapy / surgery / embolization), should be handled in the following way and once a 
lesion has had intervention then it should be treated as having intervention for the remainder 
of the study noting that an intervention will most likely shrink the size of tumors:
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
33!Step 1: the diameters of the TLs (including the lesions that have had intervention) will be 
summed and the calculation will be performed in the usual manner. If the visit response is 
PD this will remain as a valid response category. 
!Step 2: If there was no evidence of progression after step 1, treat the lesion diameter (for 
those lesions with intervention) as missing and scale up as described below, as long as 
there remain ∀1/3 of the TLs with missing measurements.  If the scaling results in a visit 
response of PD then the patient would be assigned a TL response of PD.  
!Step 3: If after both steps PD has not been assigned, then if appropriate, a scaled sum of 
diameters will be calculated (as long as ∀1/3 of the TLs with interventions), and PR or SD 
then assigned as the visit response.  Patients with intervention are evaluable for CR as long 
as all non-intervened lesions are 0 (or <10mm for lymph nodes) and the lesions that have 
been subject to intervention also has a value of 0 recorded. 
At subsequent visits the above steps will be  repeated to determine the TL and overall visit 
response.  When calculating the previous minimu m, lesions with intervention should be 
treated as missing and scaled up where appropriate (as per step 2 above).
Scaling (applicable only for lesion intervention)
If > 1/3 of target lesion measurements are treated as missing (because of intervention) then 
target lesion response will be NE, unless the sum of diameters of non-missing target lesion 
would result in PD (i.e. if using a value of [ADDRESS_972012] ill 
increased by > 20% or more compared to nadir and the sum of target lesions has increased by 5 mm from nadir).
If ≤ 1/3 of the target lesion measurements are treated as missing (because of intervention) then 
the results will be scaled up (based on the sizes at the nadir visit to give an estimated sum of 
diameters and this will be used in calculations; this is equivalent to comparing the visit sum of 
diameters of the non-missing lesions to the nadir sum of diameters excluding the lesions with 
missing measurements).
Example of scaling
Lesion Longest diameter 
at nadir visitLongest diameter 
at follow-up visit
[ADDRESS_972013] imated TL sum of 28.4cm:          
Lesions that split in two or more parts
If a TL splits in two, then the LDs of the split lesions should be summed and reported as the 
LD for the lesion that split.
Lesions that merge
If two or more TLs merge, then the LD of the merged lesion should be recorded for one of the 
TL sizes and the other TL size should be recorded as [ADDRESS_972014] and MRI, this will be considered acceptable and no adjustment within the programming is needed.  
If a change in method involves clinical examination (e.g. CT changes to clinical examination 
or vice versa), any affected lesions should be treated as missing.    
[IP_ADDRESS] Non-Target Lesions (NTLs) and New lesions.
At each visit an overall assessment of the NTL response should be recorded by [CONTACT_1275]. This section provides the definitions of the criteria used to determine and record 
overall response for NTL at the investigational site at each visit.
NTL response will be derived based on the investigator’s overall NTLs assessment as follows:  Table 8 NTL visit responses
Visit Responses Description
Complete Response (CR) Disappearance of all NTLs present at baseline with all lymph nodes non-
pathological in size (<10 mm short axis).
Progressive Disease (PD) Unequivocal progression of existing NTLs. Unequivocal progression 
may be due to an important progression in one lesion only or in several 
lesions. In all cases the progression MUST be clinically significant for the physician to consider changing (or stoppi[INVESTIGATOR_007]) therapy.
Non CR/Non PD Persistence of one or more NTLs with no evidence of progression.cm4.[PHONE_14845]#∃
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
35Table 8 NTL visit responses
Visit Responses Description
Not Evaluable (NE) Only relevant when one or some of the NTLs were not assessed and, in 
the investigator's opi[INVESTIGATOR_1649], they are not able to provide an evaluable 
overall NTL assessment at this visit.
Note: For patients without TLs at baseline, this is relevant if any of the 
NTLs were not assessed at this visit and the progression criteria have not been met.
Not Applicable (NA) Only relevant if there are no NTLs at baseline
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall level of 
substantial worsening in non-target disease such that, even in the presence of SD or PR in 
TLs, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status.
Details of any new lesions will also be recorded with the date of assessment. The presence of 
one or more new lesions is assessed as progression.
A lesion identified at a follow up assessment in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.
The finding of a new lesion should be unequivocal: i.e., not attributable to differences in 
scanning technique, change in imaging modality or findings thought to represent something 
other than tumor.
If a new lesion is equivocal, for example because of its small size, the treatment and tumor 
assessments should be continued until the new lesion has been confirmed. If repeat scans 
confirm there is a new lesion, then the progression date should be declared using the date of 
the initial scan.
New lesions will be identified via a Yes/No tick  box. The absence and presence of new lesions 
at each visit should be listed alongside the TL and NTL visit responses.
A new lesion indicates progression so the overall visit response will be PD irrespective of the 
TL and NTL response.
If the question ‘Any new lesions since baseline’ has not been answered with Yes or No and 
the new lesion details are blank this is not evidence that no new lesions are present and should 
be treated as NE in the derivation of overall visit response.
Symptomatic progression is not a descriptor for progression of NTLs: it is a reason for 
stoppi[INVESTIGATOR_528981].
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
36Patients with ‘symptomatic progression’ requ iring discontinuation  of treatment without 
objective evidence of disease progression at that time should continue to undergo tumor
assessments where possible until objective disease progression is observed.
[IP_ADDRESS] Site Investigator Assessment Using RECIST 1.1: Overall Visit Response
Table 9 Overall Visit Responses how the previously defined TL and NTL visit 
responses will be combined with new lesion information to give an overall visit response.
Table 9 Overall Visit Responses
Target Lesions Non-target lesions New Lesions Overall Response
CR CR or NA No (or NE) CR
NA CR No (or NE) CR
CR Non CR/Non PD No (or NE) PR
CR NE No (or NE) PRPR Non PD or NE or NA No (or NE) PR
SD Non PD or NE or NA No (or NE) SD
NA Non CR/Non PD No (or NE) SD NA Non PD NE SD NE Non PD or NE or NA No (or NE) NE
NA NE No (or NE) NE
PD Any Any PDAny PD Any PD
Any Any Yes PD
NA NA No NE
CR Complete response, PR Partial response, SD Stable disease, PD Progression of disease, 
NE Not evaluable, NA Not applicable (only relevant if there were no TL/NTL at baseline).
4.[ADDRESS_972015] assessments.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
374.2.1 Primary Endpoint: Overall Survival (OS)
Overall Survival (OS) is defined as the time from the date of randomization until death due to 
any cause.  Any patient not known to have died at the time of analysis will be censored based 
on the last recorded date on which the patient was known to be alive. 
Note: Survival calls will be made in the week following the date of data cut-off for the 
analysis, and if patients are confirmed to be alive or if the death d ate is post th e data cut-off 
date, these patients will be censored at the date of data cut-off.  Death dates may be found by 
[CONTACT_255750].
If a patient is known to have died but only a partial date is available then the date will be
imputed and used for derivations as follows:
!Missing day - Impute the 1stof the month. unless month is same as month of first dose of 
study drug then impute first dose date
!Missing day and month – impute 1stJanuary.
If the patient is known to be alive after an imputed death date. The date of death will be 
imputed as last date known to be alive + 1.
4.2.2 Secondary Endpoints
[IP_ADDRESS] Progression-F ree Survival (PFS)
PFS (per RECIST 1.1 as assessed by [CONTACT_713759]) will be defined as the time from the 
date of rando mization until th e date of objective disease progression or death (by [CONTACT_713760]) regardless of whether the patient withdraws from therapy or 
receives another anticancer therapy prior to progression (i.e., date of event or censoring - date of randomization +1).  Patients who have not progressed or died at the time of analysis will be 
censored at the time of the latest date of assess ment from their last evaluable RECIST 1.[ADDRESS_972016] 1.1 assessment prior to the 
2 missed visits.  Given the scheduled visit assessment scheme (i.e. assessments are scheduled 
to occur every 8 weeks), two missing visits will equate to [ADDRESS_972017] assessment, allowing for early and late visits (i.e. 2 x 8 weeks + 1 week for an early 
assessment + 1 week for a late assessment = 18 weeks). If the patient has no evaluable visits 
or does not have baseline data, they will be censored at Day 1 unless they die within 2 visits of randomization, then they will be tr eated as an event with date of death as the event date.  
Given the scheduled visit assessment scheme (i.e. eight-weekly), two missing visits will 
equate to [ADDRESS_972018] assessment, allowing for early and late visits (i.e. 2 x 8 weeks + 1 week for an early assessment + 1 week for a late assessment = 18 weeks).
The PFS time will always be derived based on scan/assessment dates not visit dates.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972019] 1.1 assessments/scans contributing towards a particular visit may be performed on 
different dates.  The following rules will be applied:
!For investigator assessments, the date of progression will be determined based on the 
earliest of the RECIST 1.1 assessment/scan dates of the component that indicates objective disease progression according to RECIST 1.1.
!When censoring a patient for PFS, the patient will be censored at the latest of the dates 
contributing to a particular overall visit assessment. 
Note: For target lesions, only the latest scan date is recorded out of all scans performed at that 
assessment for the target lesions, and similarly f or non-target lesions, only the latest scan date 
is recorded out of all scans performed at that assessment for the non-target lesions.
In the absence of significant clinical deteriora tion, the investigational site is advised to 
continue the patient on their randomized MEDI4736 + tremelimumab combination therapy, 
MEDI4736 monotherapy until objective disease progression according to RECIST 1.1.  If 
progression is not confirmed, the patient should continue their randomized MEDI4736 + 
tremelimumab combination therapy or MEDI4736 monotherapy treatment and on-treatment 
assessments. Treatment through PD in the SoC group is at the Investigator’s discretion; 
however, a second scan to confirm PD is requested for all patients in the SoC group, if 
clinically feasible.
[IP_ADDRESS] Objective Response Rate (ORR)
ORR (per RECIST 1.1 as assessed by [CONTACT_6962]) is defined as the number (%) of 
patients with at least [ADDRESS_972020] site Investigator 
tumor data.  The denominator for ORR will be all randomized patients (i.e., the FAS population).
[IP_ADDRESS] Duration of Response (DoR)
DoR (per RECIST 1.1 as assessed by [CONTACT_6962]) will be defined as the time from the 
date of first documented response until the first date of documented progression or death in 
the absence of disease progression. The end of re sponse should coincide with the date of 
progression or death from any cause used for the RECIST 1.1 PFS endpoint.  The 
denominator for DoR will be defined as described for ORR (see above).
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972021] site Investigator 
tumor data.  
[IP_ADDRESS] Disease Control Rate (DCR)
DCR at [ADDRESS_972022] objective response 
(BoR) of CR or PR in the first [ADDRESS_972023] demonstrated SD for a minimum 
interval of 24 weeks (-7 days, i.e., 161 days) following the start of treatment with IP. As 
additional analysis, DCR at [ADDRESS_972024] objective response (BoR) of CR or PR in the first [ADDRESS_972025] demonstrated 
SD for a minimum interval of 16 weeks (-7 days, i.e., 105 days) following the start of 
treatment with IP.  
DCR at [ADDRESS_972026] demonstrated SD for a minimum interval of 48 weeks (-7 days, 
i.e., 329 days) following the start of treatment with IP.  
DCR will be determined programmat ically based on RECI ST 1.1 site investigator’s tumor 
data using all data up until the first progression event.  
[IP_ADDRESS] Proportion of Patients Alive and Progression Free at 6 Months (APF6)
The APF6 will be defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed 
by [CONTACT_6962]) at 6 months.
[IP_ADDRESS] Proportion of Patients Alive and Progression Free at 12 Months (APF12)
The APF12 will be defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed 
by [CONTACT_6962]) at 12 months.
[IP_ADDRESS] Proportion of Patients Alive at 12 Months (OS12)
The OS12 will be defined as the Kaplan-Meier estimate of OS at 12 months.
[IP_ADDRESS] Proportion of Patients Alive at 18 Months (OS18)
The OS18 will be defined as the Kaplan-Meier estimate of OS at 18 months.
[IP_ADDRESS] Proportion of Patients Alive at 24 Months (OS24)
The OS24will be defined as the Kaplan-Meier estimate of OS at 24 months.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
[IP_ADDRESS] Best Objective Response (BoR)
BoR is calculated based on the overall visit responses from each RECIST 1.[ADDRESS_972027] 1.1 using the following response categories: 
CR, PR, SD, PD, and NE.
BoR will be determined programmat ically based on RECI ST 1.[ADDRESS_972028] 1.1 assessments, if the death occurs ≤17 
weeks (i.e., 16 Weeks ±7 days) after enrollment, then BoR will be assigned to the progression 
(PD) category. For patients who die with no evaluable RECIST assessments, if the death 
occurs >17 weeks (i.e., 16 weeks ±7 days) after the date of enrollment then BoR will be 
assigned to the NE category.
Progression events that have been censored due to them being >[ADDRESS_972029] 
evaluable assessment will not contribute to the BoR derivation.
[IP_ADDRESS] Time to Response
Time to response (per RECIST 1.1 as assessed by [CONTACT_6962]) is defined as the time 
from the date of first dose until the date of first documented response. The date of first 
documented response should coincide with that used for the RECIST 1.[ADDRESS_972030] documented response.
[IP_ADDRESS] Time from Randomization to First Subsequent Therapy or Death (TFST)
Time to the first subsequent therapy or death will be defined as the time from the date of 
randomization to the ear lier of either the start date of the first subsequent anticancer therapy 
after discontinuation of randomized treatment or the date of death (i.e., the date of first 
subsequent cancer therapy, death, or censoring defined as the date of randomization + 1 day).  
Any patient not known to have received a first subsequent anticancer therapy will be censored 
at the last date that the patient was known not to have received a first subsequent anticancer 
therapy.  If a patient terminated the study before the first subsequent therapy for a reason other than death, the patient will be censored at the earliest of either the patient’s last known date to 
be alive or the study termination date.
Patients not receiving randomized treatment would have TFST calculated in the same way, i.e. 
time from date of ra ndomizatio n to the subsequent anticancer therapy or d eath.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
[IP_ADDRESS] Time from Randomization to Second Subsequent Therapy or Death (TSST)
As a supportive summary to PFS2, time to second s ubsequent therapy (TSST) or death will be 
defined as the time from the date of randomization to the earlier of either the start date of the 
second subsequent anticancer therapy after discontinuation of first subsequent therapy, or the date of death.  Any patient not known to have had a second subsequent anticancer therapy will 
be censored at the last date when the patient was known not to have received a second 
subsequent anticancer therapy.  If a patient terminated the study for reason other than death 
before second subsequent anticancer therapy, the patient will be censored at the earliest of the 
last known to be alive and termination dates.
[IP_ADDRESS] Time from Randomization to Seco nd Progression-Free Survival (PFS2)
PFS2 will be defined as the time from the date of rando mization to the earliest of the 
progression event subsequent to first subsequent therapy or death.  The date of second 
progression will be recorded by [CONTACT_713761]: objective radiological 
imaging, symptomatic progression, or death.  Sec ond progression status wi ll be reviewed 
(every [ADDRESS_972031] 24 weeks relative to the date of randomization and then every 8 weeks thereafter) following the progression event used for the primary variable PFS (the 
first progression) and status recorded.  Patients alive and for whom a second disease 
progression has not been observed should be censored at the earliest of; date of withdrawal, date last known alive, DCO or, if a patient has not had a first subsequent therapy; the date last 
known not to have received a first subs equent therapy (TFST censoring date). 
[IP_ADDRESS] Change in Tumor Size
For supportive purposes percentage change from baseline in tumor size will be derived at each 
scheduled tumor assessment visit (hereafter referred to as week X for convenience). Best percentage change from baseline in tumor size will also be derived as the biggest decrease or, if no decrease, as the smallest increase in tumor size from baseline.
This is based on RECIST1.[ADDRESS_972032] evaluable assessment prior to starting treatment. The change in target lesion tumor size at week  X will be obtained for each patient by [CONTACT_713762] X and the sum of the target 
lesions at baseline. To obtain the percentage change in target lesion tumor size at week X the change in target lesion tumor size is divided by [CONTACT_713763] 100 (i.e. (week X - baseline) / baseline * 100). More details on target lesions and measurements can be found in Section 4.1.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
42Apply a window around the week X visit : Whenever tumor size data for the week X visit 
(Note: or visit at which progression was documented if before week X) is available then this 
should be used in the analysis. A windowing rule will be applied and will follow the protocol 
allowed visit window; therefore, any RECIST scan performed within ± 1 week of the protocol scheduled visit will be used for that visit.
4.3 Safety
Safety and tolerability will be assessed in terms of adverse events (AEs) (including serious 
adverse events [SAEs]), deaths, laboratory da ta, vital signs, electrocardiograms (ECGs) and 
exposure.  These will be collected for all patients. Data from all cycles of treatment will be 
combined in the presentation of safety data. ‘On treatment’ will be defined as assessments between date of start dose and 90 days following discontinuation of IP (i.e., the last dose of 
MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or SoC). For 
AEs, on treatment (or treatment-emergent AEs) will be defined as any AEs that started after dosing or prior to dosing and which worsen following exposure to the treatment (see section 
[IP_ADDRESS] for a more detailed definition).
The Safety analysis set will be used for reporting of safety data.4.3.1 Adverse Events (AEs)
AEs and SAEs will be collected from the time of signature [CONTACT_713791] [ADDRESS_972033] dose of IP (MEDI4736 + tremelimumab, 
MEDI4736, or SOC) or until initiation of another th erapy (excluding palliative radiation as 
anti-cancer therapy). Any AE occurring before treatment with IP will be included in the data 
listings but will not be included in the summary tables of AEs. 
A separate data listing of AEs occurring more than 90 days after discontinuation of 
MEDI4736 in combination with tremelimumab or MEDI4736 monotherapy will be produced.  
These events will not be included in AE summaries.
The Medical Dictionary for Regulatory Activities  (MedDRA) dictionary (using the latest or 
current MedDRA version) will be used to code the AEs. AEs will be graded according to the 
National Cancer Institute Common Terminology Criteria for AEs (CTCAE Version 4.03 or 
higher). 
AEs of Special Interest (AESIs)
Adverse events of special interest (AESIs) are events of scientific and medical interest specific 
to the further understanding of the MEDI4736 and tremelimumab safety profile and require 
close monitoring and rapid communication by [CONTACT_67852]. MEDI4736 and 
tremelimumab AESIs may be serious or non-serious. The rapid reporting of these AESIs 
allows ongoing analysis of these events in order to characterize and understand them in 
association with the use of these IPs.
The AESI’s have been identified in the CSP (Version 6) as: 
Statistical Analysis Plan 
Study Code D4193C00002
Edition Number 04Date 5 January 2018
43!Diarrhea/Colitis and intestinal perforation
!Pneumonitis/ILD
!Hepatitis/transaminase increases
!Endocrinopathies (i.e., events of hypophysitis/ hypopi[INVESTIGATOR_297], adrenal insufficiency, and 
hyperthyroidism and hypothyroidism, and type I diabetes mellitus)
!Rash/Dermatitis
!Nephritis/bl ood cr eatinine increases
!Pancreatitis/serum lipase and amylase increases
!Myocarditis
!Myositis/polymyositis
!Neuropathy/neuromuscular toxicity (eg, Guillain-Barré, and myasthenia gravis)
!Other inflammatory responses that are rare/less frequent with a potential 
immune-mediated etiology include, but are not limited to, pericarditis, sarcoidosis, uveitis and other events involving the eye, skin, hematological and rheumatological events.
An [COMPANY_008] medically qualified expert, after consultation with the Global Patient Safety 
Physician, has reviewed the AEs of special interest and identified which preferred terms 
contribute to each AESI. A further review will take place prior to database lock to ensure new terms not already included in the older MedD RA version are captured within the categories 
for the new higher MedDRA version. The list will be provided by [CONTACT_713764].
4.3.2 Treatme nt Exposure
Exposure will be defined separately for MEDI4736 monotherapy, MEDI4736 on the 
MEDI4736+ tremelimumab combination arm, tremelimumab on the 
MEDI4736+tremelimumab combination arm including retreatment, and standard of care as follows:
Total (or intended) exposure of MEDI4736 (monotherapy) 
!Total (or intended) exposure is defined as the total treatment period from first dose date of 
study drug to the earliest of “last dose date of study drug + 13 days” or death date or DCO. 
Total (or intended) exposure of MEDI4736 (combination) 
!Total (or intended) exposure is defined as the total treatment period from first dose date of 
study drug to the earliest of “last dose date of study drug + (13 days or 27 days)” or death 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
44date or DCO or start of re-treatment (applies to initial treatment period only). Twenty-
seven days will be added in the above formulae if the subject stopped dosing before week 
[ADDRESS_972034] stopped dosing at week 16 or later.
Total (or intended) exposure of tremelimumab (combination) 
!Total (or intended) exposure is defined as the total treatment period from first dose date of 
study drug to the earliest of “last dose date of st udy drug + 27 days” or death date or DCO.
For patients who are retreated; the time from last dose prior to retreatment until first dose of retreatment will be excluded from the total duration. 
Actual exposure of MEDI4736/tremelimumab
!Actual exposure is defined as above, but excluding total duration of dose delays.
Total (or intended) exposure for the SOC treatments
!The total (or intended) exposure for the SOC treatments will be calculated using the same 
principle as above, according to the dose schedule required for each SOC. The total (or intended) exposure will also be summarized by [CONTACT_713765]. Actual exposure will not be calculated for SOC.
Dose reductions are not permitted per the CSP for IP (MEDI4736 or 
MEDI4736+tremelimumab). The actual exposure calculation makes no adjustment for any dose reductions that may have occurred. 
Exposure will also be measured by [CONTACT_713766]. For the immunotherapy and 
SOC arms, a cycle corresponds to a [ADDRESS_972035] administration of study medication recorded will be used in 
the programming.
Calculation of duration of dose delays (for actual exposure):
MEDI4736 (monotherapy):
!Since Patients in the MEDI4736 monothera py treatment group will receive 10 mg/kg 
MEDI4736 via IV infusion q2w until diseas e progression, the duration of dose delays 
will be calculated as follow:
For all dosing dates:
Duration of delay = Sum of (Date of the dose - Date of previous dose – 14 days)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
45Thus, if no delays were encountered, the duration would sum up to 0, since infusions 
were done every two weeks.
MEDI4736 (given in combination):
!Since Patients in the MEDI4736 + Treme treatment group will receive 20 mg/kg 
MEDI4736 via IV infusion q4w for 4 months and tremelimumab 1 mg/kg q4w for 4 
doses followed by [CONTACT_46054]4736 monotherapy at a dose of 10 mg/kg q2w initiated [ADDRESS_972036] combination dose is administered until disease progression, the 
duration of dose delays will be calculated as follow:
For Cycle 2 to Cycle 5 (for Week 4 to Week 16) doses:
Duration1= Sum of (Date of the dos e - Date of previous dose – 28 days)
For Cycle 5 and beyond (for Week 18 and beyond) doses: Duration2= Sum of (Date of the dos e - Date of previous dose – 14 days)
Duration of delay = Duration1 + Duration2
Tremelimumab (given in combination):
!Since Patients in the MEDI4736 + Treme treatment group will receive tremelimumab 
1 mg/kg q4w for 4 doses only, the duration of dose delays will be calculated as follow:
For Cycle 2 to Cycle 4 (for Week 4 to Week 12) doses:
Duration of delay = Sum of (Date of the dose - Date of previous dose – 28 days)
4.3.3 Dose Intensity
Dose intensity will be derived for the initial treatment period and the re-treatment period 
separately for the immunotherapy agents. It will also be derived for the SOC agents. Relative 
dose intensity (RDI) is the percentage of the actual dose delivered relative to the intended dose 
through to treatment discontinuation.
Relative dose intensity (RDI) will be defined as follows for MEDI4736, tremelimumab and all 
Standard of Care therapy:
!RDI = 100% * d/D, where d is the actual cumulative dose delivered up to the actual last 
day of dosing and D is the intended cumulative dose up to the actual last day of dosing. D is the total dose that would be delivered, if there were no modification to dose or schedule.
When deriving actual dose administered the volume before and after infusion will also be 
considered.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972037] CTC grades defined for both high and 
low values: Potassium, Sodium, Magnesium, Glucose and Corrected calcium so high and low CTC grades will be calculated.
Corrected Calcium will be derived during creation of the reporting database using the 
following formulas:
Corrected calcium (mmol/L) = Total calcium (mmol/L) + ([40 – Albumin (G/L)] x 0.02)
Absolute values will be compared to the project reference range and classified as low (below 
range), normal (within range or on limits of range) and high (above range).
The maximum or minimum on treatment value (depending on the direction of an adverse 
effect) will be defined for each laboratory pa rameter as the maximum (or minimum) post-dose 
value at any time.
The denominator used in laboratory summaries of CTC grades will only include evaluable 
patients, in other words those who had sufficient data to have the possibility of an 
abnormality.
For example:
!If a CTCAE criterion involves a change from baseline, evaluable patients would have both
a pre-dose and at least [ADDRESS_972038]-dose value recorded.
!If a CTCAE criterion does not consider changes from baseline; to be evaluable, the patient 
needs only to have [ADDRESS_972039] dose of study treatment will be used 
for reporting. The Investigator’s assessment of the ECG will be collected locally. 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972040] dose.  
The denominator in vital signs data should include only those patients with recorded data.
4.3.7 General Considerations for Safety Assessments
Time windows will need defining for any presentations that summarize values by [CONTACT_765]. The 
following conventions should also apply:
!The time windows should be exhaustive so that data recorded at any time point has the 
potential to be summarized. Inclusion with in the time window should be based on the 
actual date and not the intended date of the visit.
!All unscheduled visit data should have the potential to be included in the summaries.
!The window for the visits following baseline w ill be constructed in such a way that the 
upper limit of the interval falls half way between the two visits (the lower limit of the first post-baseline visit will be Day 1).  If an even number of days exists between two 
consecutive visits, then the upper limit will be taken as the midpoint value minus [ADDRESS_972041] day after 
screening (Day -28 to -1). Day 0 should be considered the same as reporting Day 1. The 
Statistical windows only referred to reporting Day 1 to avoid confusion. 
For example, the visit windows for vital signs data in the MEDI4736 monotherapy are shown 
in the example below.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
48Visit Week Day Statistical Window
Screening NA -28 to -1 D-28 – D-1
Baseline NA D01Low – D11
V0 W0 D0 D12–D 7
V1 W2 D14 D8 – D21
V2 W4 D28 D22 – D35
V3 W6 D42 D36 – D49
V4 W8 D56 D50 – D63
V4a W10 D 70 D64 – D77
V5 W12 D84 D78 – D91
V5a W14 D 98 D92 – D105
V6 W16 D112 D106 – D119
V6a W18 D 126 D120 – D133
V7 W20 D140 D134 – D147
V7a W22 D 154 D148 – D161
V8 W24 D168 D162 – D175
V8a W26 D182 D176 – D189
V9 W28 D196 D190 – D203
V9a W30 D210 D204 – D217
V10 W32 D224 D218 – D231
V10a W34 D238 D232 – D245
V11 W36 D252 D246 – D259
V11a W38 D266 D260 – D273
V12 W40 D280 D274 – D287
V12a W42 D294 D288 – D301
V13 W44 D308 D2302 – D315
V13a W46 D322 D316 – D329
V14 W48 D336 D330 – D343
V15 W50 D350 D344 – High3
1Latest pre-dose value available  
2post-dose values only
3Note that visits up to [ADDRESS_972042] dosing date will be considered as being on treatment for the purposes 
of visit windowing and may be assigned to an on-treatment visit. Visits after this will be considered as follow-up 
and may be assigned accordingly
!For summaries showing the maximum or minimum values, the maximum/minimum value 
recorded on treatment will be used (regardless of where it falls in an interval).
!Listings should display all values contributing to a time point for a patient.
!For visit based summaries:
oIf there is more than one value per patient within a time window then the closest value 
to the scheduled visit date should be summarized, or the earlier in the event the values 
are equidistant from the nominal visit date.  The listings should highlight  the value for 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
49that patient that went into the summary table, wherever feasible. Note: in summaries of 
extreme values all post baseline values collected are used including those collected at 
unscheduled visits regardless of whether or not the value is closest to the scheduled visit date.  
oTo prevent very large tables or plots being produced that contain many cells with 
meaningless data, for each treatment group visit data should only be summarized if the number of observations is greater than the minimum of 20 and > 1/3 of patients dosed.
!For summaries at a patient level, all values should be included, regardless of whether they 
appear in a corresponding visit based summary, when deriving a patient level statistic such as a maximum. 
!Baseline will be defined as the last non-missing measurement prior to dosing with study 
treatment. For the re-treatment period then ba seline is similarly defined as the last non-
missing measurement prior to the first dose on th e re-treatment period. For laboratory data, 
any assessments made on day 1 will be considered  pre-dose. Alternatively, if two visits are 
equally eligible to assess patient status at baseline (e.g., screening and baseline 
assessments both on the same date prior to first dose with no washout or other intervention in the screening period), the average can be taken as a baseline value. For non-numeric 
laboratory tests (i.e., some of the urinalysis parameters) where taking an average is not 
possible then the best value would be taken as  baseline as this is the most conservative. In 
the scenario where there are two assessments on day 1, one with time recorded and the 
other without time recorded, the one with time recorded would be selected as baseline.
Where safety data are summarized over time, study day will be calculated in relation to date of first st udy treatment
!Missing safety data will generally not be imputed. However, safety assessment values of 
the form of “< x” (i.e., below the lower limit of quantif ication) or > x (i.e., above the upper 
limit of quantification) will be imputed as  “x” in the calculation of summary s tatistics but 
displayed as “< x” or “> x” in the listings.
!For missing diagnostic dates, if day and/or month are missing use 01 and/or Jan. If year is 
missing, put the complete date to missing.
!For missing AE start date the following will be applied:
oMissing day - Impute the first day of the month unless month is the same as month of 
the first dose of study drug then impute first dose date.
oMissing day and month – impute [ADDRESS_972043] dose date.
oCompletely missing date – impute the first dose date.
!For missing end AE dates, the following will be applied:
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972044] dose date.
oMissing day and month – impute 31stDecember unless year is the same as first dose 
date then impute last dose date.
oCompletely missing date – need to look at whether the AE/medication is still ongoing 
before imputing a date and also when it star ted in relation to study drug. If the ongoing 
flag is missing, then assume that AE is still present / medication is st ill being taken 
(i.e. do not impute a date). If the AE/medication has stopped and start date is prior to 
first dose date then impute the 1st dose date, if it started on or after first dose date then impute a date that is after the last dose date.
4.4 Patient reported outcome
PROs will be assessed using the EORTC QLQ-C30, EORTC QLQ-H&N35
.  All items/questionnaires will be scored 
according to published scoring guidelines. All PRO analyses will be based on the Full 
Analysis Set (FAS).
4.4.1 EORTC QLQ-C30
The EORTC QLQ-C30 consists of 30 questions that can be combined to produce 5 functional 
scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), and a global measure of health status.  The EORTC QLQ-C30 will be 
scored according to the EORTC QLQ-C30 scoring manual ( Fayers et al 2001 ).  An outcome 
variable consisting of a score from 0 to 100 will be derived for each of the symptom scales, each of the functional scales, and the global health status scale in the EORTC QLQ-C30 
according to the EORTC QLQ-C30 Scoring Manual.  Higher scores on the global health status 
and functioning scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity.
The change from baseline in HRQoL will be assessed using the EORTC QLQ-C30 global 
health QoL s cale, which includes 2 items from the EO RTC QLQ-C30: “How  would you rate 
your overall health during the past week?” (Item 29), and “How would you rate your overall 
QoL during the past week?” (Item 30).
Definition of clinically meaningful changes
Changes in score compared with baseline will be evaluated.  A minimum clinically 
meaningful change is defined as an absolute change in the score from baseline of ≥10 for 
scales from the EORTC QLQ-C30 ( Osoba et al 1998 ).  For example, a clinically meaningful 
improvement in physical function (as assessed by [CONTACT_26740]-C30) is defined as an 
increase in the score from baseline of ≥10, whereas a clinically meaningful deterioration is 
defined as a decrease in the score from baseline of ≥10.  At each post-baseline assessment, the 
change in symptoms/functioning from ba seline will be categorized as improvement, 
no change or deterioration as shown in Table 10 .
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
51For each subscale, if <50% of the subscale items are missing, then the subscale score will be 
divided by [CONTACT_154562]-missing items and multiplied by [CONTACT_713767] ( Fayers et al 2001 ). If at least 50% of the items are missing, then that subscale 
will be treated as missing. Missing single items are treated as missing.
The reason for any missing questionnaire will be identified and recorded. If there is evidence 
that the missing data are systematic, missing values will be handled to ensure that any possible bias is minimized.
Table 10 Change from BL and Visit Response for EORTC QLQ C30
Score Change from baseline Visit response
EORTC QLQ-C30 Global quality of life score ≥+10 Improvement
≤-10 Deterioration
Otherwise No change
EORTC QLQ-C30 symptom scales/items ≥+10 Deterioration
≤-10 Improvement
Otherwise No change
EORTC QLQ-C30 functional scales ≥+10 Improvement
≤-10 Deterioration
Otherwise No change
EORTC European Organisation for Research and Treatment of Cancer; QLQ-C30 30-item core quality of life questionnaire .
Time to symptom deterioration
For each of the symptoms scales in the EORT C QLQ-C30, time to symptom deterioration will 
be defined as the time from rando mization until th e date of the first clinically meaningful 
symptom deterioration (an increase in the score from baseline of ≥10) or death (by [CONTACT_55544]) 
in the absence of a clinically meaningful symptom deterioration, regardless of whether the 
patient withdraws from study treatment or r eceives another anticancer therapy prior to 
symptom deterioration.  Death will be included as  an event only if the death occurs within 
two visits of the last PRO assessment where the symptom change could be evaluated.  
Patients whose symptoms (as measured by [CONTACT_26740]-C30) have not shown a clinically 
meaningful deterioration and who are alive at the time of the analysis will be censored at the 
time of their last PRO assessment where the symptom could be evaluated.  Also, if symptoms 
deteriorate after two or more missed PRO assessment visits or the patient dies after two or more missed PRO assessment visits, the patien t will be censored at the time of the last PRO 
assessment where the symptom could be evaluated (prior to the two missed assessment visits).  
If a patient has no evaluable visits or does not have baseline data they will be censored at [ADDRESS_972045] baseline scores of ≤90.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
52Time to HRQoL/Function deterioration
For HRQoL, time to deterioration will be defined as the time from the date of rando mization 
until the date of the first clinically meaningful deterioration (a decrease in the function scales 
or the global health status/QoL from baseline of ≥10) or death (by [CONTACT_55544]) in the absence of 
a clinically meaningful deterioration, regardless of whether the patient withdraws from study treatment or receives another an ticancer therapy prior to HRQoL/ function dete rioration.  
Death will be included as an event only if the death occurs within [ADDRESS_972046] PRO 
assessment where the HRQoL/function change could be evaluated.  
Patients whose HRQoL (as measured by [CONTACT_26740]-C30) have not shown a clinically 
meaningful deterioration and who are alive at the time of the analysis will be censored at the 
time of their last PRO assessment where the HRQo L/function could be ev aluated.  Also, if 
HRQoL deteriorates after two or more missed PRO assessment visits or the patient dies after [ADDRESS_972047] PRO 
assessment where HRQoL/function could be evaluated.  If a patient has no evaluable visits or does not have baseline data they will be censored at 0 days.  The population for the analysis of 
time to HRQoL/function deterioration will include a subset of the FAS who have baseline 
scores of ≥10.
If a patient did not completed the questionnaire with reason being; ‘Subject too heavily 
affected by [CONTACT_713753]’ then this will be counted as a 
deterioration event.
Symptom improvement rate
The symptom improvement rate will be defined as the number (%) of patients with 
[ADDRESS_972048] 14 days apart that show a clinically meaningful improvement (a decrease from baseline score ≥10 for EORTC QLQ-C30 symptom scales) in 
that symptom from baseline.  The denominator will consist of a subset of the FAS who have a 
baseline symptom score ≥10.
HRQoL/function improvement rate
The HRQoL/function improvement rate will be defined as the number (%) of patients with 
[ADDRESS_972049] 14 days apart that show a clinically meaningful 
improvement (an increase from baseline score ≥10 for EORTC QLQ-C30 functional scales 
and global health status/QoL) in that scale from baseline.  The denominator will consist of a subset of the FAS who have a baseline HRQoL/function score ≥10.
PRO Compliance
Summary measures of overall compliance and compliance over time will be derived for the
EORTC QLQ-C30. These will be based upon:
!Received forms=number of EORTC QLQ-C30 forms plus the number not completed 
where the reason was ‘Subject too heavily affected by [CONTACT_713753]’
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
53!Expected forms= number of patients still under HRQL follow-up at the specified 
assessment time excluding patients in countries with no available translation. For patients 
that have progressed, the latest of progression and safety follow-up will be used to assess 
whether the patient is still under HRQL fo llow-up at the specified assessment time. Date 
of study discontinuation will be mapped to the nearest visit date to define the number of 
expected forms.
!Evaluable forms = subset of the expected EORTC QLQ-C30 forms with at least one 
subscale that can be determined; or where reason for non-completion was documented as 
‘Subject too affected by [CONTACT_713753]’.
Thus, the overall compliance rate is defined as number of patients with an evaluable baseline
and at least one evaluable follow-up form (as defined above), divided by [CONTACT_713768] a baseline EORTC QLQ-C30 form.
Compliance over time will be calculated separately for each visit, including baseline, as the
number of patients with an evaluable baseline form and a form at the time point (as defined
above), divided by [CONTACT_713769]. Similarly
the evaluability rate over time will be calculated se parately for each visit, including baseline,
as the number of evaluable forms (per definition above), divided by [CONTACT_688333].
4.4.2 EORTC QLQ-H&N35
The H&N35 is a head and neck cancer-specific m odule from the EORTC for head and neck 
cancer comprising 35 questions to assess head and neck cancer symptoms. The head and neck 
cancer module includes 11 single items and 7 multi-item scales that assess pain, swallowing, 
senses (taste and smell), speech, social eating, social contact, and sexuality. For all items and 
scales, high scores indicate increas ed symptomatol ogy/more problems.
The scoring approach for the H&N35 is identical in principle to that for the symptom 
scales/single items of the EORTC QLQ-C30.  As the wording is reversed on the H&N35, 
higher scores represent greater symptom severity.
Definition of clinically meaningful changes
Changes in score compared with baseline will be evaluated.  The developers of the H&N35 
have suggested that a minimum clinically meaningful change is a change in the score from baseline of >10 for s cales/items from the H&N35 module ( Bjordal et al 2000 ).  For example, a 
clinically meaningful deterioration or worsening in dry mouth (as assessed by H&N35) is 
defined as an increase in the score from baseline of ≥10.  At each post-baseline assessment, 
the change in symptoms/functioning from baseline will be categorized as improved, no 
change, or deterioration, as shown in Table 11 .  Since there is no well-established minimal 
clinically important difference for the H&N35 module, an exploratory analysis will be conducted to determine the most appropriate threshold in this patient population.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
54Table 11 Change from BL and Visit response for EORTC QLQ H&N35
Score Change from baseline Visit response
H&N35 symptom scales and items ≥+10 Deterioration
≤-10 Improvement
Otherwise No change
HRQoL Health-related quality of life; H&N35 35-item head and neck quality of life questionnaire.
Time to symptom deterioration
For each of the symptom scales/items in the H&N35, time to symptom deterioration will be 
defined as the time from the date of the first dose until the date of the first clinically 
meaningful symptom deterioration (an increase in the score from baseline of ≥10) or death (by 
[CONTACT_55544]) in the absence of a clinically meaningful symptom deterioration, regardless of whether the patient withdraws from study tr eatment or receives another anticancer therapy 
prior to symptom deterioration.  Death will be included as an event only if the death occurs 
within [ADDRESS_972050] PRO assessment where the symptom change could be evaluated.
Patients whose symptoms (as measured by [CONTACT_941] H&N35) have not shown a clinically 
meaningful deterioration and who are alive at the time of the analysis will be censored at the 
time of their last PRO assessment where the sympto m could be evaluated.  Also, if symptoms 
progress after [ADDRESS_972051] baseline scores 
≤90.
Symptom improvement rate
The symptom improvement rate will be defined as the number (%) of patients with [ADDRESS_972052] 14 days apart that show a clinically meaningful improvement 
(a decrease from baseline score >10 for H&N35 scales/items) in that symptom from baseline.
PRO Compliance
Summary measures of overall compliance and compliance over time will be derived for the
EORTC QLQ-H&N35. These will be based upon the compliance derivation described for 
EORTC QLQ-C30.
 
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
55 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
574.6 Biomarker Variables
Biomarker status will be assessed for evaluable patients according to following criteria:
!Positive: ≥ 25% tumor cell mem brane positivity for PD-L1 at any intensity above 
background staining as noted on the corresponding negative control.
!Negative: < 25% tumor cell membrane positivit y for PD-L1 at any intensity above 
background staining as noted on the corresponding negative control.
Additionally, a classification using a 1% cut point will be explored with the following criteria:
!Positive: ≥ 1% tumor cell membrane positivity for PD-L1 at any intensity above 
background staining as noted on the corresponding negative control.
!Negative: < 1% tumor cell membrane positivity for PD-L1 at any intensity above 
background staining as noted on the corresponding negative control.
 
 
5. ANALYSIS METHODS
Formal statistical analysis will be performed to test th e main hypotheses: 
!H0: No difference in OS between either MEDI4736 + tremelimumab combination therapy 
orMEDI4736 monotherapy and SoC in all patients, regardless of PD-L1 status
!H1: Difference in OS between either MEDI4736 + tremelimumab combination therapy or
MEDI4736 monotherapy and SoC in all patients, regardless of PD-L1 status
The study will be considered positive if  OS for either co-primary objective (MEDI4736 + 
tremelimumab versus SoC or MEDI4736 monotherapy versus SoC) is statistically significant.
The analysis of OS will be performed when:
!Approximately [ADDRESS_972053] occurred in 480 patients (78% maturity) across the 
MEDI4736 + tremelimumab combination therapy and SoC arms regardless of PD-L1 
status AND when approximately [ADDRESS_972054] occurred in 480 patients (78% maturity) across the MEDI4736 monotherapy and SoC arms, regardless of PD-L1 status.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
58Interim analysis for OS will be performed when  300 death even ts (80% of required events) 
have been accumulated across the MEDI4736 + tremelimumab combination therapy and SoC 
arms. It is expected that approximately [ADDRESS_972055] accumulated across the MEDI4736 monotherapy and SoC arms at this time.
5.1 General Principles
IVRS based stratification factors will be used for all analysis.  If there is >10% discordance in stratification factors as recorded in IVRS versus the Case Report Form (CRF), then a sensitivity analysis of the primary endpoint OS will be performed using CRF based 
stratification factors. 
Other general principles that will be followed throughout the study include the following:
!Descriptive statistics will be used for all variables, as appropriate, and will be presented by 
[CONTACT_1570].  Continuous variables will be summarized by [CONTACT_46932], 
mean, standard deviation, median, minimum, and maximum.  Categorical variables will be summarized by [CONTACT_383030].  
!Unless otherwise stated, percentages will be calculated out of the population total for the 
corresponding treatment arm.
!For continuous data, the mean and median will be rounded to [ADDRESS_972056] deviation will be rounded to 2 additional decimal places compared to the original data. Minimum and maximum will be displayed 
with the same accuracy as the original data. 
!For categorical data, percentages will be rounded to [ADDRESS_972057]. 
!Results of all statistical analysis will be presented using a 95% confidence interval (CI) 
and 2-sided p-value, unless otherwise stated.
!SAS® version 9.1.3 or higher will be used for all analyses.
!Unless otherwise stated all PD-L1 analyses will use the 25% cut point as defined in 
Section 4.6.
Baseline will be the last assessment of the variable under consideration prior to the intake of 
the first dose of IP, except for efficacy variables.  For efficacy variables, baseline is defined as 
the last assessment up to and including the date of rando mization. For PRO ba seline will be 
the latest assessment up to and including date of first dose. 
Efficacy and PRO data will be summarized and analyzed based on the FAS.   
  Safety data will be summarized on 
the Safety Analysis Set.
Table [ADDRESS_972058] and Cox proportional model for:
Co-primary objectives
-MEDI4736 + tremelimumab combination therapy versus SoC for 
all patients, regardless of PD-L1 status (stratified for PD-L1 
status, tumor location/HPV status, and smoking status) 
-MEDI4736 monotherapy versus SoC for all patients, regardless 
of PD-L1 status (stratified for PD-L1 status, tumor location/HPV status, and smoking status)
Secondary objectives:
-MEDI4736 + tremelimumab combination therapy versus SoC in 
PD-L1 negative patients (stratified for tumor location/HPV 
status, and smoking status)
-MEDI4736 monotherapy versus SoC in PD-L1 positive patients 
(stratified for tumor location/HPV status, and smoking status)
-MEDI4736 + tremelimumab combination therapy compared to 
MEDI4736 monotherapy in PD-L1 negative patients (stratified 
for tumor location/HPV status, and smoking status)
Sensitivity analysis:
Kaplan Meier plot of time to censoring where the censoring indicator of 
the primary analysis is reversed – attrition bias
Subgroup analyses as specified below
Progression free survival A similar analysis will be conducted as described above for overall 
survival. 
No subgroup analyses needed 
Proportion of patients alive at 
12 months, 18 months, and 24 
monthsKaplan-Meier estimates of survival at 12 months, 18 months, and 24 
months 
Objective response rate Logistic regression using site Investigator assessment (RECIST 1.1)
Duration of response Descriptive statistical and Kaplan Meier plots 
Proportion of patients alive and 
progression free at 6 and 12 months Kaplan Meier estimates of progression free survival at 6 and 12 months 
Time to treatment Response Kaplan-Meier plots using site Investigator data (RECIST 1.1)
Time to first and second subsequent 
therapy (TFST, TSST)Stratified log-rank test
Time from randomization to second 
progression (PFS2)Stratified log-rank test
Disease control rate Logistic regression using site Investigator data (RECIST 1.1)
Best objective response N (%) using site Investigator data (RECIST 1.1)
Symptom improvement rate 
(EORTC QLQ-C30 and EORTC 
QLQ-H&N35 endpoints)Logistic regression
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
60Table 12 Pre-planned statistical and sensitivity analyses to be conducted
Endpoints analyzed Notes
QoL/Function improvement rate 
(EORTC QLQ-C30 endpoints)Logistic regression
Time to QoL/Function deterioration 
(EORTC QLQ-C30 endpoints)Stratified log-rank test
Time to symptom deterioration 
(EORTC QLQ-C30 and EORTC 
QLQ-H&N35 endpoints)Stratified log-rank test
  
CI Confidence interval; irRC Immune-related response criteria; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 
version 1.1; OS Overall survival. 
5.1.1 Multiple Testing Strategy
In order to strongly control the type I error at 5% (2-sided), a Multiple Testing Procedure 
(MTP) will be used across the co-primary objectives (OS in MEDI4736 + tremelimumab combination therapy versus SoC and OS in MEDI4736 monotherapy versus SoC), and across 
the analysis populations (all patients re gardless of PD-L1 status and PD L1-negative 
population). If the highe st level hypothesis in the MTP is rejected for superiority, the 
remaining hypothesis will then be tested as shown in Figure 4 below.
Hypotheses will be tested using an MTP with an alpha recycling strategy ( Burman et al 2009 ).  
The levels of the MTP are shown in Figure 4 . Of note, the comparisons of MEDI4736 + 
tremelimumab combination therapy versus MEDI4736 monotherapy will not be included in 
the MTP, and therefore will not be conducted under strict alpha control.
According to alpha (test mass) splitting and alpha recycling, the test mass that becomes 
available after each rejected hypothesis is recycled to the next hypotheses not yet rejected.  
Since OS is tested at multiple timepoints (i.e., 1 interim analysis and final analysis) the OS 
tests for the same comparison/population (i.e., shown in box 2 in the MTP) will be considered as [ADDRESS_972059] mass is allocated to a non-rejected hypothesis 
in the multiple testing procedure.  Implementation of this pre-defined ordered testing 
procedure, including recycling, w ill strongly control type I error at 5% (2-sided), among all 
key hypotheses.  
There will be one interim analysis of OS, conducted after approximately 80% of the target 
death events have been observed across MEDI4736 + tremelimumab combination therapy and 
SoC arms, and across MEDI4736 monotherapy a nd SoC arms, regardless of PD-L1 status. 
The alpha level allocated to OS for MEDI4736 + tremelimumab combination therapy versus 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
61SoC and MEDI4736 monotherapy versus SoC (all patients, regardless of PD-L1 status), will 
be controlled at the interim and final analysis time points by [CONTACT_713770] ( Lan and DeMets 1983 ) that approximates an O’Brien Fleming approach, where the 
alpha level applied at the interim depends upon the proportion of information available.  If 
statist ically si gnificant, then testing for OS will continue in the PD-L1-negative population.  A 
separate spending function (based on observed in formation fraction in this subgroup) w ill be 
used to adjust the alpha levels at the interim and final analyses in the PD-L1-negative 
population.
Figure 4 Levels of the Multiple Testing Strategy
Combo: MEDI4736 + tremelimumab.
Mono: MEDI4736 monotherapy.
OS Overall survival; PD-L1 negative Patients with PD-L1–negative tumors; SoC Standard of Care.
No other study objectives will be considered in the formal multiple testing procedure.
5.2 Analysis Methods
5.2.1 Overall Survival (OS)
Analysis of the Co-Primary Variables
The primary analysis of OS in MEDI4736 + tremelimumab and MEDI4736 monotherapy, in 
all patients, regardless of PD-L1 status will be done using a stratified log-rank test stratified 
by [CONTACT_4002]-L1 status (positive and negative), tumor lo cation/ HPV status (oropharyngeal cancer 
with HPV positive status, oropharyngeal cancer with HPV negative status, and non-
oropharyngeal cancer regardless of HPV status), and smoking status (>10 and ≤10 packyears). 
The effect of treatment will be estimated by [CONTACT_514296] 95 % CI and p-value, using the Breslow approach for handling ties ( Breslow 1974 ), as described in the 
multiple strategy (Section 5.1).   

Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
62The covariates in the statis tical mod elling will be based on the values entered into 
IVRS/IWRS at randomization, even if it is subsequently discovered that these values were 
incorrect.
The HR and its CI will be estimated from a stratified Cox proportional hazards model ( Cox 
1972 ) with treatment as the only factor and the same strata information as above (with ties = 
Efron and any stratification variables included in the strata statement). 
Secondary Variables
OS will be analyzed in PD-L1-negative patients using a stratified log-rank test, adjusting for 
tumor location/HPV status, and smoking status.  
For the comparisons of MEDI4736 + tremelimumab combination therapy versus SoC in 
PDL1-negative patients, treatment effects will be estimated by [CONTACT_713771] 95% CIs and p-values using the appropriate alpha, as described in the multiple 
strategy above (Section 5.1). The HR and its CI will be estimated from a stratified Cox 
proportion al hazards model ( Cox 1972 ) with treatment as the only factor and the same strata 
information as above.
Kaplan-Meier plots of OS will be presented by [CONTACT_2939].  Summaries of the number and 
percentage of patients who have died, those still in survival follow-up, those lost to follow-up, and those who have withdrawn consent will be provided along with the median OS for each 
treatment. 
A similar analysis will be conducted to compare MEDI4736 monotherapy versus SoC in the 
PD-L1 positive patients as described above.
In addition, a secondary analysis of OS will be performed to compare MEDI4736 + 
tremelimumab combination therapy versus MEDI4736 monotherapy in the PD-L1-negative 
population as de scribed above.
Analysis of OS in Subgroup Populations 
For each one of the fo llowing subpopulations: 
!PD-L1 status (positive, negative ) from eCRF using a 25% cut point
!PD-L1 status (positive, nega tive) using a 1% cut point
!Tumor location/ HPV Status (oropharyngeal cancer with HPV positive status, 
oropharyngeal cancer with HPV negative status, and non-oropharyngeal cancer regardless 
of HPV status) from eCRF
!Primary tumor site (oral cavity, oropharynx, hypopharynx and larynx)
!Smoking Status (>10 and ≤10 pack-years) from eCRF
Statistical Analysis Plan 
Study Code D4193C00002
Edition Number 04Date 5 January 2018
63!Smoking history (current, former, never)
!Use of chewing tobacco, oral snuff, and sublingual nicotine (Yes vs. No)
!Sex (male and female)
!Age at randomization (<65, ≥65 – 75, and ≥75 years of age)
!Race (Asian, non-Asian)
!ECOG Performance status (0 and ≥1)
!Prior radiation therapy (Yes vs. No)
!Time to recurrence from platinum-containing multimodality therapy (<6 months, ≥6 
months or presentation with metastatic disease)
!Prior lines of systemic therapy (1, 2, and ≥3)
!Metastatic disease at baseline (stage IVc and other stages)
!Extent of Disease (recurrent and metastatic)
!Standard of Care (cetuximab, taxane, methotrexate, fluoropyrimidine-based regimen) if 
there is sufficient data for the analysis.
The comparisons will include MEDI4736 + tremelimumab combination therapy versus SoC 
and MEDI4736 monotherapy versus SoC for all patients regardless of PD-L1 status. For PD-
L1 negative patients and PD-L1 positive pati ents, the comparisons will include MEDI4736 + 
tremelimumab combination therapy versus SoC MEDI4736 monotherapy versus SoC, and MEDI4736 + tremelimumab combination therapy versus MEDI4736 monotherapy. Treatment 
effect will be estimated by [CONTACT_514296] 95% CI using an 
unstratified Cox model with treatment as the only covariate. For standard of care subgroup analysis, only the SoC of interest will be included as a treatment factor (e.g. for comparison of 
MEDI4736 monotherapy versus cetuximab, the treatment factors will be MEDI4736 
monotherapy and cetuximab). 
Other baseline variables may also be assesse d if there is clinical ju stification or if an 
imbalance is observed between the treatment arms. The purpose of the subgroup analyses is to 
assess the consistency of treatment effect across expected prognostic and/or predictive factors. Only HR estimate along with 95% CI will be presented. No adjustment to the significance 
level for testing of the subgroup and sensitivity analyses will be made since all these analyses
will be considered supportive of the analysis of OS.
If there are too few events available for a meaningful analysis of a particular subgroup (it is 
not considered appropriate to present analyses where there are less than 20 events in a 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
64subgroup), the relationship between that subgroup and the primary endpoint (OS) will not be 
formally analysed. In this case, only descriptive summaries will be provided.
A forest plot will be presented comp aring OS for MEDI4736 + tremelimumab combination 
therapy vs. SoC (in all patients regardless of PD-L1 status and in PD-L1 negative patients) 
and MEDI4736 monotherapy vs. SoC (in all patients regardless of PD-L1 status) within each 
subgroup.
Analysis of OS12, OS18, and OS24
OS12, OS18 and OS24 will be summarized (using th e Kaplan-Meier curve) and presented by 
[CONTACT_2939].  
Assumptions of Proportionality
For OS presented by [CONTACT_713772]-L1 status, the assumption of 
proportionality will be assessed.  Proportional hazards will be tested first by [CONTACT_713773]-log (event times) versus log (time) and, if these raise concerns, by 
[CONTACT_6486] a time-dependent covariate to assess the extent to which this represents random variation.  If a lack of proportionality is evident, the variation in treatment effect will be 
described by [CONTACT_514298][INVESTIGATOR_713740].  In such 
circumstances, the HR can still be meani ngfully interpreted as an average HR over time unless 
there is extensive crossing of the survival curves.  If lack of proportionality is found, this may 
be a result of treatment-by-covariate interactions, which will be investigated.
Sensitivity Analysis
A sensitivity analysis for OS will examine the censoring patterns to rule out attrition bias, 
achieved by a Kaplan-Meier plot of time to censoring where the censoring indicator of OS is reversed.
The number of patients prematurely censored w ill be summarized by [CONTACT_2939]. A patient 
would be defined as prematurely censored if their survival status was not defined at the data cut-off. In addition, duration of follow-up will be summarized using medians:
!In censored patients who are alive at data cut-off only: Time from randomization to date of 
censoring (date last known to be alive) by [CONTACT_2939].
!In all patients: Time from randomization to the date of death (i.e. overall survival) or to 
the date of censoring for censored patients regardless of treatment arm.
Effect of covariates on the HR estimate (Cox Proportional Hazards model)
An unstratified Cox proportional hazards modeling w ill be employed to assess the effect of 
covariates on the HR estimate for the overall popu lation. The following covariates will be 
included in the statistical model: treatment and the stratification factors as main effects (PD-
L1 status, Tumor location/HPV S tatus (oropharyngeal cancer with HPV positive status, 
oropharyngeal cancer with HPV negative status, and non-oropharyngeal cancer regardless of HPV status), and smoking status).
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972060], adjusted for 
pre-specified baseline prognostic factors. For this analysis, a stratified Cox adjusted for the 
following covariates will be used. They are:
!PD-L1 status
!Tumor location/ HPV Status (oropharyngeal cancer with HPV status positive, 
oropharyngeal cancer with HPV status negative and non-oropharyngeal cancer regardless 
of HPV status)
!Smoking Status (>10 and ≤10 pack-years)
!Time to recurrence from multimodality therapy (<6 months versus ≥6 months or 
presentation with metastatic disease)
!Sex at randomization
!Age at randomization
The two models described above will include the effect regardless of whether the inclusion of 
effect significantly improves the fit of the model providing there is enough data to make them meaningful.
Interactions between treatment and the stratification factors will also be tested to rule out any 
qualitative interaction using the approach of Gail and Simon [ADDRESS_972061] of changing (crossover outside of this study) to immunotherapi[INVESTIGATOR_014] (or other 
potentially active investigational agents) on overall survival analyses
Exploratory analyses of OS adjusting for the impact of subsequent immunotherapy or other 
investigational treatment may be performed  if a meaningful proportion of pati ents change 
therapy (>15%).  Methods such as Rank Preserving Structural Failure Time ( Robins and 
Tsiatis 1991 ), Inverse Probability of Censoring Weighting ( Robins 1993 ), and other methods 
in development will be explored.  The plausi bility of the underlying assumptions and impact 
of model selection will be inve stigated as sensitivities to the default methods.  Baseline and 
time-dependent characteristics will be explored, and summaries of baseline characteristics will 
be generated by [CONTACT_2939], desi gnating between those that have and haven’t changed 
immunotherapi[INVESTIGATOR_713741].  
Further detail will be provided in the Payer Analysis Plan. These analyses are intended to 
support reimbursement appraisals. Subsequent therapi[INVESTIGATOR_713742]. Patients who subsequently 
received an immunotherapy agent or entered an immunotherapy trial will be summarized and 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
66listed by [CONTACT_19480] m according to line of subsequent therapy, i.e. immediately after 
immunotherapy or as a later line.
5.2.2 Progression F ree Survival (PFS)
PFS analyses will be based on the programmatically derived RECIST 1.[ADDRESS_972062] of treatment will be estimated by [CONTACT_584259] 
p-value.  Kaplan-Meier plots of PFS will be presented by [CONTACT_2939].  Summaries of the 
number and percentage of patients experiencing a PFS event and the type of event (RECIST 1.1 or death) will be provided along with median PFS for each treatment.
The assumption of proportionality will be assessed in the same way as for OS.
The analysis will be repeated in the PD-L1 positive and negative groups adjusting for tumor 
location/HPV status, and smoking status.  
5.2.3 Objective Response Rate (ORR)
The ORR will be based on the programmatically derived RECIST 1.1 using the site 
Investigator data. The ORR will be compared between MEDI4736 + tremelimumab 
combination therapy versus SoC and MED I4736 monotherapy versus SoC using logistic 
regression models adjusting for the same factors as the co-primary variables. The results of the 
analysis will be presented in terms of an odds ratio together with its associated profile 
likelihood 95% CI and p-value ((e.g. using the option ‘LRCI’ in SAS procedure GENMOD) and p-values (based on twice the change in  log-likelihood resulting from the addition of a 
treatment factor to the model).  
Summaries will be produced that present the number and percentage of patients with a tumor 
response (CR/PR).  Overall visit response data will be listed and summarized over time for all 
patients (i.e., the FAS).
The analysis will be repeated for the PD-L1 pos itive and negative groups adjusting for tumor 
location/HPV status, and smoking status.  
5.2.[ADDRESS_972063] Objective Response (BoR) 
BoR, based on site investigator data (RECIST 1.1), w ill be su mmarized by n (%) for each 
category (CR, PR, SD, PD, and NE), per treatmen t arm. No formal s tatistical analyses are 
planned for BoR.
5.2.5 Disease Control Rate (DCR) 
The DCR as per site investigator data (RECIST 1.1) will be analyzed using logistic 
regressions as described in section 5.2.3 for ORR.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
675.2.6 Duration of Response (DoR)
Descriptive data will be provided for the D oR in responding patients  by [CONTACT_2939], 
including the Kaplan-Meier curves (without any formal comparison of treatment arms or p-
value attached). Swimmer plots will be produced. This depi[INVESTIGATOR_713743]’s nature and 
duration of response as a separate bar (horizontally) over time.
5.2.7 Proportion of Patients Alive and Progression Free at 6 and 12 Months 
The APF6 and APF12 will be summarized (using the Kaplan-Meier curve) and presented by 
[CONTACT_2939].  
5.2.8 Time to Response (TTR)
The TTR, based upon the site investigator data, will be summarized (i.e., number of patients 
[%] based upon the number of responders) by [CONTACT_713774].  Additionally, descriptive summary statistics (i.e., minimum, 
maximum, median, Q1 and Q3) will also be presented. 
5.2.9 Time from Randomization to Second Progression (PFS2)
Second progression (PFS2) will be analyzed using ident ical methods as outlined for the 
analysis of PFS and adjusting for the same set of covariates.  Medians and Kaplan–Meier plots will be presented to support the analysis.
5.2.[ADDRESS_972064] (TFST) and the second (TSST)
subsequent therapy or death will be analyzed using the same methodology and model as that 
used for the analysis of PFS.  The HR for the treatment effect together with its 95% CI will be presented.  In addition, a Kaplan-Meier plot of the time to the start of first and the second 
subsequent therapy will be presented by [CONTACT_2939], and the time between progression and 
start of first and the second subsequent therapy will be assessed. This interval will be summarized per treatment arm, but no formal co mparisons will be made.  No multiplicity 
adjustment will be applied as this is viewed as a supportive endpoint.
In patients who received subsequent anticancer therapy, a summary table of first and the 
second subsequent anticancer therapi[INVESTIGATOR_637708], as well as response 
to first and the second subsequent anticancer therapy by [CONTACT_2939] (if available).
The number of patients prematurely censored will also be summarized.5.2.[ADDRESS_972065] change in target lesion tumor size from baseline, (where best change in target lesion 
size is the maximum reduction from bas eline or the minimum increase from baseline in the 
absence of a reduction) will also be summarized and presented.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972066]’s 
best percentage change in tumor size as a separate bar, with the bars ordered from the largest 
increase to the largest decrease. Reference lines at the +20% and –30% change in tumor size 
levels will be added to the plots, which correspond with the definitions of progression and 
‘partial’ response respectively. Additionally, ‘spi[INVESTIGATOR_108027]’ plots will be produced. This depi[INVESTIGATOR_713744]’s percentage change in tumor size as a line over time. Additional waterfall plots showing percentage change in tumor size at specific timepoints may be produced if it is felt 
that these are warranted to provide greater clarity. 
The above outputs will be programmed for the investigator site data based upon RECIST 1.1 
assessments. 
5.2.12 Patient Reported Outcome (PRO)
The PRO endpoints that have been identified as secondary are EORTC QLQ-C30 time to
HRQoL deterioration for global health status, time to symptom deterioration for fatigue, time 
to symptom deterioration for functional deter ioration for physical domain and QLQ-H&N35 
time to symptom deterioration for these 2 symptoms; pain and swallowing. These are not part 
of the main multiple testing procedures and as supportive endpoints will need a Bonferroni 
adjustment to the significance level to aid in terpretation. Therefore, these 5 endpoints will be 
tested at a 1.0% significance level and 99% CIs will be produced. Also, 95% CIs will be 
produced. 
The other time to symptom deterioration endpoints will be tested at a 5% significance level
and 95% CIs will be produced.
[IP_ADDRESS] EORTC QLQ-C30
Time to symptom deterioration will be analyzed for each of the 3 symptom scales (fatigue, 
pain, and nausea/vomiting).  Time to HRQoL/function deterioration will be analyzed for the 
5 function scales (physical, role, emotional, cognitive, and social) and global health status/QoL. 
This will be achieved by [CONTACT_713775] a stratified log-rank test and 
stratified Cox proportional hazards model (to get The HR and its CI) as described for the analysis of the co-primary variables of OS.   
Time to deterioration will be presented using a Kaplan-Meier plot for each of the 3 symptom 
scales (fatigue, pain, and nausea/vomiting), 5 functional scales (physical, role, emotional, cognitive, and social), and global h ealth s tatus/QoL. 
A summary of the symptom improvement rate for each of the 3 symptom scales (fatigue, pain, 
and nausea/vomiting) items will be produced.  Similarly, a summary of HRQoL/function 
improvement rate for each of the 5 function scales (physical, role, emotional, cognitive, and 
social) and global health status/QoL will be  produced.  Symptom improvement rate and 
HRQoL/function improvement rate will be analyzed by [CONTACT_713776]  D4193C00002
Edition Number 04Date 5 January 2018
69using a logistic regression model as described for the analysis of ORR. If there are too few 
responses for a meaningful analysis formal analysis will not be performed and only summaries 
presented (it is not considered appropriate to perform formal tests if there are fewer than 10 responses in a subgroup/scale).
Summaries of absolute and change from baseline values for each of the 3 symptom 
scales/items (fatigue, pain, and nausea/vomiting), 5 individual symptom items (dyspnoea, insomnia, appetite loss, constipation, and diarrhoea), 5 functional scales (physical, role, 
emotional, cognitive, and social), and the glob al health status\QoL sc ore will be reported by 
[CONTACT_512217].  Graphical presentations may also be produced as appropriate.  
[IP_ADDRESS] EORTC QLQ-H&N35Time to symptom deterioration for each of the 4 symptom scales/ items in the QLQ-H&N35 
(pain, swallowing, senses and speech) will be compared between treatment arms using a 
stratified log-rank test and stratified Cox proportional hazards model (to get The HR and its 
CI) as described for the analysis of the co-primary variables of OS.  
For each of these 4 symptom scales/ items in the QLQ-H&N35 above, time to deterioration in 
symptoms will be presented using a Kaplan-Meier plot.  
A summary of the symptom improvement rate for each of the 4 symptom scales/items (pain, 
swallowing, senses and speech) will be produced.  The symptom improvement rate will be 
compared between treatment groups using a logistic regression model as described for ORR.
If there are too few responses for a meaningful analysis formal analysis will not be performed and only summaries presented (it is not consid ered appropriate to perform formal tests if there 
are fewer than 10 responses in a subgroup/scale).  
Summaries of absolute and change from baseline values for each of the 7 symptom scale/item 
(pain, swallowing, senses, speech, social eating, social contact [CONTACT_713777]) and 11 single-
item measures (teeth, problems with mout h opening, dry mouth, sticky saliva, coughing, 
feeling ill, use of analgesics, use of nutritional supplements, use of a feeding tube, weight gain, and weight loss) will be reported by  [CONTACT_150138].  Graphical 
presentations may also be produced as appropriate.
 
 
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
70 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS] PRO Compliance
Overall compliance and compliance over time will be summarized for each PRO scale and 
subscales of interest (EORTC QLQ-C30, QLQ-H&N35,   
.
5.2.13 Safety
Safety data will be summarized. No  formal statistical analyses will be performed on the safety 
data. All safety and tolerability da ta will be using the safety population.  
The following sections describe the planned safety summaries for AEs, vital signs, laboratory 
parameters, ECG and WHO performance status. However, additional safety tables (not 
specified in this SAP) may need to be produced  to aid interpretation of the safety data.
[IP_ADDRESS] Adverse Events
All AEs, both in terms of current Medical Dictionary for Regulatory Activities (MedDRA) 
preferred term and Common Toxicity Criteria for Adverse Events (CTCAE) grade, will be 
listed and summarized descriptively by [CONTACT_248640] (n) and percentage (%). The current MedDRA 
dictionary will be used for coding. Any AE occurring before treatment with IP will be 
included in the AE listings, but will not be included in the summary tables (unless otherwise 
stated). These will be referred to as ‘pre-treatment’. However, any AE occurring before the 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972067] subsequent therapy (excluding palliative radiation as a subsequent therapy) following 
discontinuation of IP (whichever occurs first) will be used for reporting of all of the AE summary tables. This will more accurately depi[INVESTIGATOR_713745] [ADDRESS_972068] that a number of AEs up to 90 days following discontinuation are likely to be attributable to subsequent therapy. However, to assess the long term toxicity profile, a small selection of 
the AE summaries may be repeated containing AEs observed up until 90 days following 
discontinuation of IP (i.e. without taking subsequent therapy into account). A small selection of AE summaries may also be produced containing AEs observed from initiation of the first 
subsequent therapy following discontinuation  of IP until 90 days following discontinuation of 
IP treatment (i.e. summarising those AEs experienced by [CONTACT_713778] [ADDRESS_972069] discontinuation of IP). These outputs 
will only be produced if the number of AEs observed warrant the inclusion of such outputs for 
interpretational purposes. Any data post [ADDRESS_972070] dose will be listed only apart from a 
separate summary that presents any events that occur prior to dosing or starting more than 90 
days after discontinuing IP. 
All reported AEs will be listed along with the date of onset, date of resolution (if AE is 
resolved) and investigator’s assessment of severi ty and relationship to study drug. Frequencies 
and percentages of patients reporting each preferred term will be presented (i.e. multiple 
events per patient will not be accounted for apart from on the epi[INVESTIGATOR_713746]). 
Summary information (the number and percent of patients by [CONTACT_72065]) will be tabulated for:
!All AEs 
!All AEs causally related to study medication
!AEs with CTCAE grade 3 or 4
!AEs with CTCAE grade 3 or 4, causally related to study medication
!AEs with outcome of death
!AEs with outcome of death causally related to study medication
!All SAEs
!All SAEs causally related to study medication 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
72!AEs leading to discontinua tion of study medication
!AEs leading to discontinuation of study me dication, causally related to study medication
!Immune mediated AEs based on pre-defined criteria presented in the immune mediated 
AE charter and/or per eCRF (representing physician’s evaluation). Footnotes will be added in the summary tables to specify how the immune mediated AEs were identified (i.e. by [CONTACT_713779]/physician’s evaluation). 
!Infusion reaction AEs
An overall summary of the number and percentage of patients in each category will be 
presented, as will an overall summary of the number of epi[INVESTIGATOR_713747].  In 
addition, a truncated AE table of most common AE s, showing all events that occur in at least 
5% of patients overall will be summarized by [CONTACT_11702], by [CONTACT_713780]4736 + tremelimumab arm.  This cut-off may be modified after review of the data.
When applying a cut-off (e.g., 5%), the raw percentage should be compared to the cut-off, no 
rounding should be applied first (i.e., an AE with frequency of 4.9% will not appear if a cut-
off is 5%).
Each AE event rate (per 1000 patient years) will also be summarized by [CONTACT_713781]. For each preferred term, the event rate (defined as the number of 
patients with that AE divided by [CONTACT_126948]-up across all patients in each group multiplied by 1000) will be presented.
AEs will be assigned CTCAE grades (National Cancer Institute (NCI) CTCAE version 4.03) 
and summaries of the number and percentage of patients will be provided by [CONTACT_713782] , system organ class, preferred term. 
Fluctuations observed in CTCAE grades during study will be listed for those AEs which are 
CTCAE ≥ 3.
Summaries of the number and percentage of patients with AEs leading to dose interruptions of 
IP will be presented by [CONTACT_11702].
In addition, AEs with outcome of death, SAEs, AEs leading to discontinuation of treatment, 
and AEs causally related to IP will be listed.
A summary of deaths will be provided with number and percentage of patients, categorized as:
!Related to disease under investigation, 
!AE outcome = death,
!Both related to disease under investigation and with AE outcome=death, 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
73!Patients with unknown reason for death and
!Other deaths.
A corresponding listing will also be produced. 
Adverse Events of Special Interest 
Preferred terms used to identify adverse events of special interest will be listed before 
database lock (DBL) and documented in the Study Master File. Grouped summary tables of 
certain MedDRA preferred terms will be produced.  For each ‘grouped’ term, the number (%) of patients experiencing any of the specified terms will be presented by [CONTACT_128918]. Additional summaries will include Time to Onset of first CTCAE grade [ADDRESS_972071] AE for each grouped term and preferred term within it will also be produced. Groupi[INVESTIGATOR_713748], and a listing of the preferred terms in each groupi[INVESTIGATOR_184111].
Additional summaries of the above-mentioned grouped AE categories w ill include number 
(%) of patients who have:
!At least one adverse event of special interest presented by [CONTACT_305846]
!At least one adverse event of special interest by [CONTACT_3229]
!At least one adverse event of special interest causally related to study medication
!At least one adverse event of special interest leading to discontinuation of IP
A summary of total duration (days) includi ng median duration of AESI will be provided for 
events which have an end date and this will be supported by [CONTACT_713783]-off, as well as a summary of time to resolution to grade 1 or 
less and time to resolution to grade 2 or less. 
Additionally, there will be several summaries  of AESIs requiring concomitant treatment, and 
particularly the relationship of AESIs to the use of immunosuppressive agents (i.e., depi[INVESTIGATOR_713749]) and, separately, to the use of immunosuppressive agents at high doses (High dose is defined as >= 40mg of prednisone or 
equivalent per day). Furthermore, median treatment duration of steroids/immunosuppressant 
will be provided.
Haemorrhages adverse events 
Key summary tables will also be produced considering selected hemorrhage adverse events.
Summary information (the number and percent of patients by [CONTACT_72065]) will be tabulated for:
!All Haemorrhage AEs, including event rate
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
74!Time to onset
!All Haemorrhage AEs causally related to study medication
!All Haemorrhage AEs with maximum CTCAE grade
!Haemorrhage AEs with CTCAE grade 3 or 4
!Haemorrhage AEs with CTCAE grade 3 or 4, causally related to study medication
!All deaths 
!Haemorrhage AEs with outcome of death
!AEs with outcome of death causally related to study medication
!All SAEs
!All SAEs causally related to study medication 
!AEs leading to discontinua tion of study medication
!AEs leading to discontinuation of study me dication, causally related to study medication
!Impact of concomitant medication with potential risk of bleeding on the occurrence of the 
most severe bleed within each patient
!Medical history of bleeding in patients who experience bleeding AEs
Additionally, a listing of all Haemorrhage SAEs a nd Haemorrhage adverse event patients who 
experience death and will be provided.
Summary of long term tolerability
To assess long term tolerability , provided th at there are a sufficient number of patients with 
events to warrant it, prevalence plots, life tab le plots and cumulative in cidence plots will be 
presented for each of the AESI grouped terms and any other events considered important after 
review of the safety data, provided there are ≥ [ADDRESS_972072] dose of study treatment is calculated as 
the number of patients experiencing the event divided by [CONTACT_713784]-up at time t; generally, t is categorized by [CONTACT_713785].  The prevalence will be plotted over time presented. Multiple occurrences of the same 
event are considered for each patient but a patient is only counted in the numerator whilst theyare experiencing one of the occurrences of the event. These plots will only be produced for 
AESIs that have ≥[ADDRESS_972073] onset for each AE will also be produced (e.g. 1-28 days, 29-56 days, 57- 84 days, 85-112 days, >112 days).  Median 
duration of the AE will be presented in patients who experienced each AE, as well as the 
median time to resolution to grade [ADDRESS_972074], or in other words, the 
probability of having an AE in  a specified time period (e.g. 0-1 months, 1-3 months, 3-6 
months, etc.) given that the patient reaches that time period without having an event is plotted 
for each time period.  These plots will only be produced for AESIs that have ≥[ADDRESS_972075] occurrence of 
the event by a given time point. The cumulativ e incidence function estimates the cumulative 
incidence if the data cut-off had not been imposed and all patients had completed safety 
follow-up ( Pi[INVESTIGATOR_33008] M 2006). These plots will only be produced for AESIs that have ≥10 
events.
[IP_ADDRESS] Laboratory Assessments
Data obtained up until the [ADDRESS_972076] subsequent therapy following discontinuation  of IP (whichever occurs first) will be used 
for reporting. This will more accurately depi[INVESTIGATOR_713750] a 
number of toxicities up to 90 days following di scontinuation of IP are likely to be attributable 
to subsequent therapy. However, to assess the long term toxicity profile, a small selection of 
the summaries of laboratory data will be repeated containing data collected up until 90 days 
following discontinuation of IP (i.e., without tak ing subsequent therapy into account). A small 
selection of summaries of laboratory data will also be produced containing data from initiation 
of the first subsequent therapy followi ng discontinuation of IP until 90 days following 
discontinuation of IP (i.e., summarising th e laboratory data collected on patients taking 
subsequent therapy during the [ADDRESS_972077] discontinuation of IP). These 
outputs will only be produced if the number of laboratory toxicities observed warrant the 
inclusion of such outputs for interpretational purposes. Any data post [ADDRESS_972078] dose will be listed only.
Data summaries and listings will be provided in International System (SI) of units.
All laboratory data will be listed. Flags will be applied to values falling outside - reference 
ranges (which will be explicitly noted on these listings where applicable), and to values for 
which CTC grading applies.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
76Scatter plots (shift plots) of baseline to maximum value on treatment as well as plots for 
baseline to minimum value on treatment (on treatment is defined as data collected between the 
start of treatment and the relevant follow-up period following the last dose of IP) will be produced for: clinical chemistry (ALT, AST, ALP, total bilirubin, corrected calcium, 
magnesium, sodium, potassium, creatinine, albumin, corrected calcium, magnesium, sodium, 
potassium, gamma glutamyl transferase a nd glucose) and haematology (haemoglobin, 
lymphocyte (count, absolute), ne utrophils (count, absolute), pl atelet count and leukocytes).
If clinically indicated; box-plots of absolute values by [CONTACT_5875], and box-plots of change from 
baseline by [CONTACT_5875], may be presented for haemoglobin; neutrophil count, absolute; lymphocyte count, absolute; platelet count; AST; ALT; ALP; Total bilirubin; albumin; total protein; 
corrected calcium; phosphate; sodium; potassium; creatinine and urea nitrogen.
Shift tables for laboratory values by [CONTACT_529070] (CTC) grade will be 
produced, and for specific parameters separate shift tables indicating hyper- and hypo-
directionality of  change will be produced. The laboratory par ameters for which CTC grade 
shift outputs will be produced are:
!Haematology: Haemoglobin, Leukocytes, Lymphoc ytes (absolute count), Neutrophils 
(absolute count), Platelets
!Clinical chemistry: ALT, AST, Alkaline P hosphatase (ALP), Total bilirubin, Albumin, 
Magnesium – hypo and – hyper, Phosphate –hypo and -hyper, Sodium – hypo and –hyper, Potassium – hypo and – hyper, Corrected calcium – hypo and – hyper, Glucose –
hypo and – hyper, GGT, Bicarbonate, Creatinine
Additional summaries will include a shift table for urinalysis (Bilirubin, Blood, Glucose, 
Ketones, Protein) comparing baseline value to maximum on treatment value.
Note that for leukocyte differentials (lymphocy tes, monocytes, neutroph ils), SI units are 
considered absolute counts, not % values, so should all be converted to 10**9/L. This conversion to absolute counts is achieved by [CONTACT_518058] % value by [CONTACT_713786].
Hy's law
The following summaries will include the number (%) of patients who have:
!Elevated ALT, AST, and Total bilirubin during the study
oALT ≥ 3x –<= 5x, > 5x – <=8x, > 8x - < 10x, > 10x - <= 20x, and > 20x Upper Limit 
of Normal (ULN) during the study
oAST≥ 3x – <=5x, > 5x – <=8x, > 8x - <= 10x, > 10x - <= 20x. and > 20x ULN 
during the study
oTotal bilirubin ≥2x - <= 3x, >3x - <=5x, and >5x ULN during the study
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
77!Narratives will be provided for potential Hy’s law cases defined as an increase in serum 
AST or ALT ≥ 3x ULN preceding, or coincident with, Total Bilirubin ≥ 2xULN, 
irrespective of serum Alkaline Phosphatase (ALP), at any point during the study following 
the start of randomised therapy.
Liver biochemistry test results over time for pati ents with elevated ALT or AST, and elevated 
total bilirubin (at any time) will be plotted.  Individual patient data where ALT or AST plus 
Total bilirubin are elevated at any time will be listed also.
Plots of ALT and AST vs. Total bilirubin will also be produced with reference lines at 3×ULN 
for ALT, AST, and 2×ULN for Total bilirubin. In each plot, Total bilirubin will be in the 
vertical axis.
Abnormal Thyroid function
Elevated TSH will be summarized per treatment group in terms of number (%) of patients 
with elevated TSH (higher than the upper normal range), low TSH (lower than lower normal 
range), elevated TSH post-dose and within normal range at baseline, low TSH post-dose and 
within normal range at baseline.
[IP_ADDRESS] ECGs
ECG data obtained up until the 30 day safety follow-up visit will be included in the summary 
tables of QT changes.
Overall evaluation of ECG is collected at screening and as clinically indicated in terms of 
normal or abnormal, and the rele vance of the abnormality is termed as “clinically significant” 
or “not clinically significant”. 
[IP_ADDRESS] Vital Signs
Box plots for absolute values and change from baseline by [CONTACT_713787]. 
5.2.14 WHO/ECOG Performance Status
All WHO/ECOG performance status will be summari zed over time for FAS.
 
 
 
 
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
78 
 
 
 
 
 
 
5.2.17 Demographi c, Initial Diagnostics and Baseline Characteristics Data
The following will be listed and summarized for all patients in the FAS (unless otherwise 
specified):
!Patient disposition (including screening failures and reason for screening failure) 
!Important protocol deviations specified in this SAP
!Inclusion in analysis populations
!Demographics (age, age group [<65, ≥65 – <75, and ≥75 years], sex, race and ethnicity)
!Patient characteristics at baseline weight, weight group [<70, ≥70 – <90, and ≥ 90 kg], 
Body Mass Index (BMI) [<18.5, ≥18.5 – 25.0, ≥25.0 – <30.0, ≥30.0 kg/m2].
!Patient recruitment by [CONTACT_713788]
!Previous disease-related treatment modalities
!Number of regimens of previous chemotherapy for SCCHN at baseline
!Previous head and neck cancer therapy
!Disease characteristics at baseline (WHO /ECOG performance status, best response to 
previous therapy)
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
79!Disease characteristics at initial diagnosis (primary tumor location, histology type, tumor 
grade, time from diagnosis to first dose, overall disease classification, AJCC staging)
!Time to recurrence from last dose of platinum in a platinum-containing multimodality 
therapy (<6 months, ≥6 months)
!Extent of disease at baseline
!Disease related medical history
!Time from most recent disease progression to randomization
!Post-discontinuation cancer therapy
!Smoking status (>10 versus ≤10 pack-years)
!PD-L1 status (positive, negative) for all patients treated and also from those who have 
screened.
!Tumor location/HPV S tatus (oropharyngeal cancer with HPV positive status, 
oropharyngeal cancer with HPV negative status, and non-oropharyngeal cancer regardless of HPV status)
!Stratification factors by [CONTACT_713789] (unless otherwise specified) per 
ICH guidelines:
!Important protocol deviations specified in this SAP 
!Subject excluded from analysis populations 
!Demographics (age, age group [<65, ≥65 – <75, and ≥75 years], sex, race and ethnicity)
The AZ drug dictionary (AZDD) will be used for concomitant medication coding.
5.2.18 Treatment Exposure
The following summaries related to MEDI4736 , tremelimumab, and SoC will be produced for 
the safety analysis set:
!Total exposure.
!Actual exposure (Actual exposure will not be provided for SoC patients).
!Number of dose interruptions. 
!RDI (entire intended treatment period). 
For patients on study treatment at the time of the ORR and OS analysis, the DCO date will be 
used to calculate exposure. Summaries of exposure will also be presented for the subgroup of 
discontinued patients.
All treatment information data (study drug administration, MEDI4736, tremelimumab and 
SoC) will be listed for the safety analysis set.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date [ADDRESS_972079] summaries 
produced, together with number of regimens received. Moreover, a descriptive summary will be produced for time to subsequent therapy from  discontinuation of study drug treatment. 
6. INTERIM ANALYSIS
Interim safety monitoring will be conducted by [CONTACT_41774]. Details of the plan and 
communication process will be provided in an IDMC Charter. 
In addition, 1 interim analysis for OS will be performed for superiority when a total of 
approximately 300 death events (80% of required events) have been accumulated across the 
MEDI4736 + tremelimumab combination therapy and SoC arms in all patients, regardless of 
PD-L1 status; it is expected that approximately [ADDRESS_972080] accumulated across the MEDI4736 monotherapy and SoC arms at this t ime. The Lan-DeMets spending function that 
approximates an O’Brien Fleming approach will be used to account  for the multiplicity 
introduced by [CONTACT_713790] (Lan and DeMets 1983). 
If exactly 80% of target death information is av ailable at the time of the interim analysis, that 
is, 300/[ADDRESS_972081] been accumulated across MEDI4736 + tremelimumab 
combination therapy and SoC arms; and approximately 300/[ADDRESS_972082] been accumulated across MEDI4736 monotherapy and SoC arms, in all patients, regardless of PD-
L1 status, the 2-sided significance level to be applied for the interim and final analyses would 
be 1.0% and 2.2%, respectively for each co-primary objective. If the interim analyses indicate superiority in both of the co-primary objectives , then subsequent analysis of the secondary 
objective will be performed in accordance with the multiple testing strategy. A separate Lan-
DeMets (O’Brien Fleming) spending function will be used to determine the alpha levels at the interim and final analyses for the secondary objective, as applicable. If the interim analysis 
results do not meet the criterion for stoppi [INVESTIGATOR_713751]-primary 
objective, then follow-up will continue until approximately [ADDRESS_972083] been accumulated across MEDI4736 +tremelimumab combin ation therapy and SoC arms regardless 
of PD-L1 status; and approximately [ADDRESS_972084] accumulated across MEDI4736 
monotherapy and SoC arms in all patients, regardless of PD-L1 status. OS will be analyzed in all patients, regardless of PD-L1 status and in  PD-L1-negative populations at the final 
analysis. 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
817. CHANGES OF ANALYSIS FROM PROTOCOL
Table 13 Changes of Analysis from Protocol
Section of 
SAP Affected
(If applicable)Change Rationale
Section 1.1.[ADDRESS_972085] and second subsequent therapy (TFST, 
TSST) are supportive of anti-tumor activity. PFS2 analysis was mentioned in the protocol, 
but PFS2 was not identified in 
the secondary endpoints. It was added for consistency.
Section 3 The analysis sets table 12 in the CSP indicates 
that DoR and DCR will be analyzed in both the 
PDL1 negative and positive analysis sets. These subset analysis won’t be performed. The inclusion of DoR and 
DCR subset analyses were not 
intended.
Section 4.1 The following ‘(based on observed information 
fraction in this subgroup)’ was added: A separate 
spending function (based on observed information 
fraction in this subgroup) will be used to adjust 
the alpha levels at the interim and final analyses in the PD-L1-negative population.Clarification of text, no change 
to methodology.
Section 5 The following sentence was updated from either 
to both: If the interim analyses indicate superiority
in both of the co-primary objectives, then subsequent analysis of the secondary objective 
will be performed in accordance with the multiple 
testing strategy.This was a mistake in the 
protocol text.
Section 5  The following sentence was removed: Similarly, 
if the criterion for stoppi[INVESTIGATOR_713752]-primary objective, but is not met in the secondary objective (PD-L1-negative population) at that 
time, then follow-up will continue until the final 
target number of deaths in the PD-L1-negative population has been observed. The final analysis 
in the PD-L1- negative population will then be 
conducted.  Section was not updated when 
protocol was amended. Now 
consistent with protocol.
  
 
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
82Table 13 Changes of Analysis from Protocol
Section of 
SAP Affected
(If applicable)Change Rationale
Section 5 Landmark analyses (OS12, OS18, OS24, PFS6, 
PFS12) will not be form ally analyzed (using the 
methods of Klein et al). Formal analysis was not 
considered necessary to 
support interpretation beyond 
the Kaplan Meier estimates of the median event times.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
838. REFERENCES
Bjordal et al 2000
Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, et al, for 
the EORTC Quality of Life Group. A 12 country field study of the EORTC QLQ-C30 
(version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer 2000;36(14):1796-807.
Breslow 1974
Breslow, NE. Covariance Analysis of Censored Survival Data. Biometrics. 1974; 30:89–99
Burman et al 2009
Burman CF, Sone sson C, Guilbaud O. A recycling framework for the construction of 
Bonferroni-based multiple tests. Statistics in Medicine 2009;28:739-61.
Cox [ADDRESS_972086]. Regression models and life-tables. J Royal Stat Society 1972;Series B 34(2):187-
220.
Fayers et al 2001
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the 
EORTC Quality of Life Group.  The EORTC QLQ-C30 Scoring Manual (3
rd edition).
Published by: [CONTACT_67383], Brussels 2001.
Gail and Simon 1985
Gail M, Simon R. Tests for qualitative interactions between treatment effects and patient
subsets. Biometrics 1985 Jun;41(2):361–72.
 
Lan and DeMets 1983
Lan KKG and DeMets DL. Discrete sequential boundaries for clinical trials. 
Biometrika 1983;70(3):659-63.
Osoba et al 1998
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in
health-r elated quality-of-life scores. J Clin Oncol 1998;16(1):139-44.
Statistical Analysis Plan 
Study Code  D4193C00002
Edition Number 04Date 5 January 2018
84Pardoll 2012
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews:
cancer 2012;12:252.
Pi[INVESTIGATOR_33008] M.  2006
Competing risks: A practical perspective.  Wiley.
Robins 1993
Robins JM. Information Recovery and Bias Adjustment in Proportional Hazards Regression 
Analysis of Randomized Trials Using Surrogate Markers. Proceedings of the 
Biopharmaceutical Section, American Statistical Association 1993; 24-33.
Robins and Tsiatis 1991
Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank 
preserving structural failure time models. Commun ications in Statistics-Theory and Methods 
1991; 20(8):2609-31.
Shin and Khuri 2013
Shin DM, Khuri FR. Advances in the management of recurrent or metastatic squamous cell
carcinoma of the head and neck. Head Neck 2013;35(3):443-53.
Vermorken et al 2008
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based
chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27.
9. APPENDIX (NOT APPLICABLE)